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Abstract 
The six-membered rings have a priviledged presence in both natural products and synthetic 
compounds such as drug molecules. Multiple methods to prepare them in the laboratory 
have been developed. The Diels-Alder reaction provides several pathways toward the 
construction of substituted six-membered rings with a high degree of regio-, diastereo- and 
enantioselectivity. It can be considered to be the most important and powerful carbon-
carbon bond-forming reaction of all, in synthetic organic chemistry. 
 
A practical synthetic method for the preparation of hexahydrocinnolines was developed 
here, as part of continuing research on polymer-supported pericyclic reactions in 
preparation of biologically interesting compounds. Some cinnoline derivatives from the 
literature were reported to show interesting biological properties, such as antimicrobial 
activity and inhibition of cancer cell lines. Hexahydro-1,2,4-triazolocinnoline-1,3-diones 
and related compounds were synthesized via aza Diels-Alder reaction on solid-phase.  
 
Protein kinases are key regulators of cell function that constitute one of the largest and most 
functionally diverse gene families. By adding phosphate groups to substrate proteins, kinase 
driven phosphorylation plays a significant role in a wide range of cellular processes. More 
than 500 protein kinase genes are present in the the human genome, constituting about 2% 
of all human genes. They regulate many cellular processes such as growth, differentiation, 
and proliferation. Protein kinases are seen as potential therapeutic targets since their 
mutation and dysregulation is causal in multiple human diseases, including metabolic, 
immunological  disorders,  and  cancer.  The  consistent  structure  of  the  catalytic  site  among  
protein kinases sets limits for the development of protein kinase inhibitors. Some protein 
kinases, however, have regulatory domains as part of their structure, such as protein kinase 
C (PKC), whose regulatory (C1) domain is unique and is found only in a small number of 
kinases. This offers a selectivity advantage, thus making the C1-domain an attractive drug 
target.  In  fact,  the  utilization  of  the  the  X-ray  crystal  structure  of  the  PKC? C1b domain, 
with molecular modeling, led to the discovery, in this work, of novel C1 domain ligands, 
the  tricyclic  ?-amino  alcohols.  Synthesis  of  these  compounds  was  achieved  by  the  
utilization of the Diels-Alder reactions. 
 
In the process of modifying a naturally occurring deep-blue colored hydrocarbon 
guaiazulene, a novel aminoguaiazulene derivative was synthesized. This novel derivative 
undergoes ring annulation reactions with 1,2-dicarbonyl reagents to yield tricyclic ?-
lactams, types of benzo[cd]azulenes. Benzo[cd]azulenes derived from guaiazulene, are 
colorful synthetic carbocyclics with interesting chemical and biological properties. Some of 
the benzo[cd]azulenes synthesized in this study were recently characterized as selective Pim 
kinase inhibitors. Pim kinases have become intriguing targets for cancer therapy that 
possess unique structural features, among protein kinases, that offer a great potential in the 
design of selective Pim-inhibitors. Based on the promising Pim-kinase inhibition results 
from multiple cell-based assays, a further modification of the benzo[cd]azulenes was 
conducted, where some interesting findings in their chemical behavior were observed; new 
phenolic benzo[cd]azulene compounds were formed, with potent Pim-inhibitory activities. 
The benzo[cd]azulenes developed in this study were found to be useful research 
compounds, potential Pim-selective kinase inhibitors, and putative anti-cancer drug 
candidates. The new synthetic methods detailed in this study will be valuable tools in the 
further development of additional benzo[cd]azulenes and related systems in the future. 
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“Chemical synthesis always has some element of 
 planning in it. But, the planning should never been  
too rigid. Because in fact, the specific objective the  
 synthetic chemist uses as the excuse for his activity 
         is often not of special importance in the general 
   sense, rather, the important things are those that 
  he finds out in the course of attempting his objective.”  
  
R. B. Woodward 
Nobel Prize laureate in chemistry (1965) 
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1 Introduction 
The fact that natural compounds are mostly composed of cyclic structures has made the 
cyclization reactions perhaps the most important pathways in organic chemistry. The 
challenge to mimic living organisms in their ability to build complex molecular structures in 
near quantitative conversions, and with complete stereocontrol, forms an ultimate driving 
force and inspiration to the scientists working in the field of synthetic organic chemistry. 
 
As a generalization, alicyclic (aliphatic and cyclic) compounds hardly differ in their 
chemical properties from their open-chain analogs. As stated by Nobel Prize laureate 
Leopold Ruži?ka in 1945, “Many investigations have shown however, that in spite of this 
close  chemical  similarity,  the  alicyclic  analogs  can  exhibit  entirely  different  physiological  
properties.”1 August Kekulé, the principal founder of the theory of chemical structure, first 
introduced the carbon six-membered ring into structural chemistry in his formula for 
benzene in 1865.2 Since then the six-membered ring maintained its unique position in the 
classification of organic chemistry.  
 
The privileged presence of six-membered ring structures in biologically interesting 
molecules is obvious. Natural products, such as carbohydrates (glucose), DNA bases 
(adenine), alkaloids (quinine), and cholesterol-reducing lovastatin carry the six-membered 
ring(s) as a pivotal element in their structure. Similarly, synthetic compounds, such as 
drugs, also carry six-membered rings, as exemplified in antiviral oseltamivir and B-raf 
kinase inhibitor vemurafenib. With the continued discovery of increasingly complex 
polycyclic natural compounds, the need to understand how and why six-membered rings 
form becomes ever more important. 
 
 
 
Multiple synthetic methods for the preparation of six-membered rings exist. Some selected 
examples from the literature are listed with examples of the particular six-member ring 
forming reactions utilized in the natural product synthesis in Table 1. The Diels-Alder 
reaction is covered in detail in the literature review, since it represents a major contribution 
to this thesis and is not listed in Table 1. 
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Table 1.          Selected methods for preparation of six-membered rings in natural product synthesis. 
Method Example References 
Robinson 
annulations 
 
Robinson,3 
Wieland4 
Intramolecular 
Michael reaction 
 
Majetich,5 
Evans6 
Intramolecular 
ene reaction 
 
Oppolzer 
and 
Snieckus7 
(review) 
Polyene (cation-
olefin) cyclization 
 
 
Johnson8 
(review), 
Abe9 
(review) 
Free radical 
cyclization 
  
Jasperse10 
(review) 
 
Electrocyclic 
reactions 
 
 
Nicolaou11 
Dieckmann 
condensation 
 
Powers12 
Ring closing 
metathesis 
 
 
Fürstner13 
(review), 
Deiters14 
(review), 
Beckmann 
rearrangement 
 
 
 
White15 
 
The literature review that follows in Chapter 2 is divided into two sections. The first part 
concentrates on the methods for construction of the six-membered rings of 
benzo[cd]azulenes; colourful synthetic carbocyclic compounds with interesting chemical 
and biological properties. A general review of the Diels-Alder reaction covering historical 
and basic principles is provided, since it constitutes a major contribution to ring synthesis in 
this thesis work. Both solution and solid-phase methods are included. The second part 
concentrates on the biology and inhibition of two protein kinases, namely protein kinase C 
and Pim kinases (Pim-1, Pim-2 and Pim-3), both phosphoryl transferring enzymes that are 
central  to  this  study.  The  results  of  the  work  from  the  reported  publications  I–IV  are  
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detailed in Chapter 5, which describes the development of a practical synthetic method for 
the preparation of biologically interesting six-membered ring compounds by Diels-Alder 
reactions on solid-phase. By selecting carbonylazo compounds as highly reactive N=N 
azadienophiles with polymer-bound diene, solid-phase synthesis of hexahydrocinnolines 
was introduced. 
Utilization  of  the  the  X-ray  crystal  structure  of  the  PKC? C1b  domain  combined  with  
molecular modeling, (3-aminodecahydro-1,4-methanonaphthalen-2-yl)methanol was 
discovered as a novel C1-domain ligand. This led to the synthesis of two tricyclic ?-amino 
alcohols, where the construction of their decahydronaphthalene core with six continuous 
stereocenters was achieved by extensive utilization of the Diels-Alder reaction. 
During the modification studies of guaiazulene, a naturally occurring deep-blue coloured 
bicyclic sesquiterpenoid hydrocarbon, a method for nitrogen insertion into the seven-
member ring, was developed. Guaiazulene 4-carboxylic acid was converted to the novel 7-
isopropyl-1-methylazulen-4-amine in two reaction steps. Further elaboration with 1,2-
dicarbonyl electrophiles led to the synthesis of ?-lactams with a six-membered heterocyclic 
ring fused to azulenes aromatic core.  
Some of the benzo[cd]azulenes synthesized in our laboratory were recently characterized 
as selective Pim kinase inhibitors. Based on the promising results for Pim kinase inhibition 
in multiple cell-based assays, a further modification of the benzo[cd]azulenes was 
conducted with an aim to develop more potent Pim inhibitors. In addition, during the course 
of modification of benzo[cd]azulen-3-ones, some interesting findings in their chemical 
behavior were observed. This led to the synthesis of new phenolic benzo[cd]azulene 
compounds with potent Pim-inhibitory activities. Some of the studied benzo[cd]azulenes 
were able to inhibit intracellular activities of Pim kinases with promising low-micromolar 
EC50 values. Furthermore, treatment with benzo[cd]azulenes significantly slows down 
migration of adherent cancer cells derived from either prostate-  cancer or squamocellular 
carcinomas. Development of additional benzo[cd]azulenes derivatives is expected to further 
improve their efficacy as Pim-selective kinase inhibitors and possible anti-tumor drug 
candidates. 
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 2 Review of the literature 
2.1 Synthesis of six-membered ring of benzo[cd]azulenes 
 
 
 
Azulene (1) and guaiazulene (2)  are  hydrocarbons  consisting  of  a  five-  and  a  seven-
membered rings fused to form an unsaturated bicyclic system. The azulene (1) can be 
considered an isomer of naphthalene (3). Whereas naphthalene is colorless, azulenes are 
intensely blue. The history of azulenes dates back to the 15th century when it was 
recognized as the azure-blue chromophore obtained by steam distillation of German 
chamomile (Matricaria chamomilla L.). The chromophore was discovered in 1863 by 
Septimus Piesse,16 who applied the descriptive name azulene to azure-blue distillates 
discovered in yarrow and wormwood. Its structure was first reported by Lavoslav Ruži?ka, 
followed by its synthesis in 1937 by Plattner and Pfau,17 who named the parent compound 
of the family as bicyclo[5.3.0]decapentaene. These compounds are now collectively 
referred to as the azulenes. 
The benzo[cd]azulene system (4) has attracted interest due to its unique theoretical 
property as an odd nonalternant analog of phenalene.18 Boekelheide and Smith were among 
the first to report the synthesis of 2H-benzo[cd]azulenes.19 The parent compound (5) was 
prepared by means of a difficult multistep route based on the carbene-mediated ring 
expansion of the acenaphthene framework. 2H-benzo[cd]azulene  (5), was however only 
obtained in small quantities and is very susceptible to polymerization, thus can only be 
handled at low temperatures in dilute solution.19 Previously, Hafner and Schaum had 
reported the synthesis of 3,4,7,9-tetramethyl-2H-benzo[cd]azulene (6)20 by base-catalyzed 
cyclization. This crystalline product is however susceptible to decomposition. The six-
membered ring of 7-(tert-butyl)-4-hydroxy-9-methyl-3H-benzo[cd]azulen-3-one can be 
synthesized in similar manner.21 Syntheses of (6) and (7), however, were reported without 
yields or adequate experimental procedures. 
Hafner  and  Rieper  reported  the  synthesis  of  2H-benzo[cd]azulenes by [2+2]-
cycloaddition of cyclopenta[cd]azulene (8) with in situ generated ethoxycarbonylcarbene 
followed by its ring expansion (Scheme 1).22 The copper-catalyzed thermolysis of ethyl 
diazoacetate at 90–110 °C in the presence of (8) leads directly to the 2H-benzo[cd]azulene 
framework. In a one-pot procedure a regioselective cycloaddition of (8) giving (9) is 
probably followed by valence isomerization of the latter to compound (10), which 
undergoes a [1,8]-hydrogen shift to stable 7,9-dimethyl-2H-benzo[cd]azulene-4-carboxylate 
(11a) in 60% yield. When R is methyl or phenyl, the cycloaddition occurs in similar fashion 
to the same site of cyclopenta[cd]azulene to yield the 3-methyl (11b) and 3-phenyl (11c) 
analogs in 64% and 59% yields, respectively. 
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Me
Me
Me
Me
R
-N2
Me
Me
R
H CO2Et
regioselective site in
[2+2]-cycloaddition
H CO2Et
R
Me
Me
CO2Et
R
[1,8]-shift
Cu/
N2CHCO2Et
(8)
(9) (10) R = H (11a), Me (11b),Ph (11c)
H
H
 
Scheme 1.  Carbene-mediated ring-expansion strategy to 2H-benzo[cd]azulenes. 
 
McGlinchey et al.23 synthesized benzo[cd]azulenes by extending the guaiazulene (2) carbon 
framework through nucleophilic addition of the resonance-stabilized anion (12)  to  ?-
chloroketones (Scheme 2). The diastereomeric alcohols (13) were used for the subsequent 
reaction, whereby the formation of the six-member rings in (cis/trans-14) was accomplished 
through AlCl3-promoted Friedel-Crafts alkylation. Finally, the subsequent treatment of 
alcohols  (14)  with  POCl3, followed by refluxing in pyridine for 8 hours enabled the [1,5] 
sigmatropic rearrangements leading to the desired 2H-benzo[cd]azulene (15a) and to the 
oxidized  heptafulvene (16a) in 59% and 9% yields, respectively (Scheme 2). For the 
alcohol (15b)  the  conversion  to  its  4-tert-butylbenzo[cd]azulene (15b) and its oxidized 
analog (16b) was accomplished in less drastic conditions (30 °C, 3 h) and in slightly better 
yields (61% and 23%, respectively). 
 
Scheme 2.  McGlinchey’s approach to benzo[cd]azulenes and heptafulvenes. 
 
The same authors reported an interesting reaction of TCNE (tetracyanoethylene) with 
benzo[cd]azulene (15b) at room temperature to produce the tetracyclic Diels-Alder adduct 
(17) (Scheme 2) in 96% yield.23 On the other hand, the oxidized heptafulvene (16b) 
participates not in [4+2], yet in a regioselective [2+2] cycloaddition across the C6–C7 
double bond. The cycloaddition chemistry of heptafulvenes and related systems has been 
comprehensively reviewed.24 
Abe et al.25,26 communicated  the  synthesis  of  7H-naphtho[cd]azulen-7-ones, which are 
structurally related to the benzo[cd]azulenyl system. Intramolecular Friedel-Crafts 
cyclization of diethyl 4-phenylazulene-1,3-dicarboxylate (18) with polyphosphoric acid 
(PPA) at 100 °C for 7 h gives a mixture of two tetracyclic products, (19) in 10% yield, and 
14 
(20) in 60% yield (Scheme 3). The same reaction performed at room temperature for 2 days, 
gives the ethyl ester (20) as a single product (67%). Alkaline ester hydrolysis of (20) and 
the following decarboxylation upon heating in hot PPA for 3 h yields (19) in 61% yield. 2-
Substituted analogs of (18) (R = Me, Ph, Cl) gave similalrly derivatives (19 and 20).25  
The Friedel-Crafts cyclization is not only restricted to the 4-phenyl derivatives. While 
the cyclization of 4-(?-naphthyl)azulene-1,3-dicarboxylates with polyphosphoric acid yields 
pentacyclic 7H-azuleno[1,8-bc]phenanthren-7-ones (21a–b) as main products,25 the 4-vinyl 
derivatives under similar conditions (PPA, rt, 1 d) give tricyclic benzo[cd]azulones (22a–b) 
(Scheme 3).27 
 
 
Scheme 3.  Friedel-Crafts cyclizations to fused tri-, tetra- and pentacyclic azulenones. 
 
When the monocarboxylic acid (23) is heated in PPA at 100 °C for 3 hours, tetracyclic 
product (24)  is  obtained  in  90% yield  (Scheme 3).28 The chloro substituent is replaceable 
with nucleophilic reagents to give the corresponding substitution products. Thus, the 
treatment of (24) in methanol with sodium methoxide (reflux, 1 h) gives 6-methoxy-
substituted naphtho[cd]azulen-7-one (25) in a quantitative yield. When heated in 48% 
hydrobromic acid (90 °C, 40 min), (25) is easily hydrolyzed to give a quantitative yield of 
an acidic compound (26).28 The ring carbonyl in (26) is found to be highly polarized28 and 
can exist as a tautomeric mixture. The authors showed spectroscopically (IR) that (26) 
exists as a mixture of (26a) and (26b), in which (26a) predominates.28 
 
Neidlein et al.29,30 have  reported  the  synthesis  of  3H-benzo[cd]azulen-3-ones (Scheme 4) 
starting from 4,6,8-trimethylazulene (27a) and 4-methylazulene (27b). Regioselective 
metalation of (X) with LDA, followed by treating the anion (28)  with  bromoacetic  acid,  
gave azulene 4-propionic acids (29a–29b). These groups undergo cyclization upon heating 
to 4,5-dihydro-3H-benzo[cd]azulen-3-ones (30a, 57%, 30b,  73%)  in  the  precence  of  p-
toluenesulfonic acid. Finally, oxidation of (30a–30b) with DDQ (2,3-dichloro-5,6-
dicyanobenzoquinone) at 110 °C yields the fully conjugated benzo[cd]azulen-3-ones (31a, 
31b). The enol tautomer of (31b) can be trapped by O-alkylation to give 
ethoxy[cd]benzazulenium tetrafluoroborate (32) (Scheme 4). 
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Scheme 4.  Synthesis of 3H-benzo[cd]azulen-3-ones. 
 
Very recently, Aumüller et al. published a communication where they describe a facile 
four-step synthesis of tricyclic benzo[cd]azulen-3-ones from commercially available 
guaiazulene (2) (Scheme 5).31 The nucleophilic attack of the guaiazulene-derived carbanion 
proceeds predominantly at the ketone carbonyl instead of the ester carbonyl of the 
carboxylic acid esters (33).  The  utilization  of  (33)  offers  an  advantage  over  the  use  of  
bromoacetic acid, as different substituents (R) can be introduced in the 4-position of the 
resulting benzo[cd]azulene skeleton. After the succesful hydrolysis of esters (34) with 
lithium hydroxide, the corresponding carboxylic acids take part in the acid-catalyzed 
intramolecular electrophilic acylations, as reported previously by Neidlein et al.29,30 for a 
related system. When R is a trifluoromethyl or methyl, the 4,5-dihydrobenzo[cd]azulen-3-
ones (35a–b) are isolable in high yields (92%, 80%, respectively) but only with a modest 
yield with a hydrogen (35c, 32%). The ?-hydroxy ketones (35a–c) were converted to fully 
conjugated benzo[cd]azulen-3-ones (36a–c) by the one-pot mesylation/ base-assisted 
elimination sequence. 
 
 
Scheme 5. Syntheses of 4-substituted benzo[cd]azulen-3-ones 
 
The same authors reported a successful application of an interesting acid-catalyzed 
tautomerization reaction that proceeds via isomerization  of  ?-bonds  across  the  azulene  
moieties of tricyclic benzo[cd]azulen-3-ones (Scheme 6). Concentrated hydrochloric acid 
was found to be a suitable catalyst for the initial protonation of the carbonyl oxygens of 
(36a–c) leading to the formation of cationic benzo[cd]azulenium species (37) being 
detectable by intensive and rapid color change from green to bright orange/red. 
Subsequently, the positive charge in (37)  is  stabilized  by  the  release  of  a  proton  from the  
alkyl substituent in the eight-position to form the phenols (38) with a fulvene-type exocyclic 
16 
double bond on the seven-membered ring, resembling McGlinchey’s tricyclic 
heptafulvenes.23 The primary tautomerized products could not be isolated as phenols (38)  
due to the reverse nature of the reaction. However, in situ derivatization by deprotonation 
with a strong base (sodium hydride), followed by methylation (dimethyl sulphate), allows 
the isolation of heptafulvenic reaction products as orange phenol ethers (39a–c).31 
 
 
Scheme 6. Acid-mediated tautomerization of benzo[cd]azulen-3-ones to heptafulvenes. 
 
Aumüller et  al.32 communicated also a facile two-step synthesis of heptafulvenes from 
guaiazulene (2). Electrophilic aromatic substitution reactions between dicarbonyl 
electrophiles (40)  and  C3  of  guaiazulene  (2) proceed without an added catalyst in high 
yields (Scheme 7). The intermediate methylene carbanions generated in situ from  3-
hydroxyacyl azulenes (41a–b) instantly attack the neighboring carbonyl group to form the 
six-membered ring of the benzo[cd]azulene skeleton (Scheme 7). The subsequent one-pot 
elimination of the corresponding alcohol gives the enolates (42), which are stabilized by an 
aromatic  cyclopentadienyl  anion.  Alkylation,  silylation,  or  protonation  of  enolates  (42) 
leads to intermediates (43). The addition of HCl readily initiates an interesting type of acid-
catalyzed elimination reaction, where the release of a proton from the alkyl substituents at 
the 8-position leads to the formation of semicyclic C=C double bonds, which characterize 
the tricyclic products as heptafulvenes (44a–d) with variable substituents on 3- and 4-
positions of the six-membered ring. 
The phenylketone in (41c) accounts for a different route, since the cyclized intermediate 
is an alkoxide that cannot be converted into an enolate. After deprotonation with DBU (1,8-
diazabicyclo[5.4.0]undec-7-ene) followed by the double elimination of water, however, 4-
phenyl-substituted heptafulvene (44e) is isolated in excellent yield (86%) (Scheme 7); this 
represents the highest yield of the entire series. 
 
The same authors expanded the scope of the method by examining the oxidations of the 
heptafulvenes (44a–e) (Scheme 8). Syntheses of tropones via heptafulvenes are not well 
documented in the literature and the cleavage of C=C double bonds is unusual for mCPBA 
(m-chloroperoxybenzoic acid). The hypothetical reaction mechanism suggests the epoxide 
is formed first (45) by 1 equiv of mCPBA. Presumably, the epoxide is prone to ring-opening 
reactions, due to the effective stabilization of the positive charge by the conjugated ?-
system (the seven-membered ring) in the resulting cations (46). Subsequently, the acyl 
peroxides (47) are formed by nucleophilic attack of another equivalent of mCPBA. Finally, 
the exit of the leaving group mCBA initiates the fragmentation of (47), yielding tropones 
(48a–e) with moderate to high yields (48–82%) and acetone as a byproduct.32 Evidence that 
supports the described reaction mechanism was recently obtained by rapid analysis of 
reaction intermediates by electrospray ionization-mass spectrometry.33 The mCPBA 
oxidation of phenolic heptafulvene (44c)  led  to  the  identification  of  an  ion  at  m/z 515 
([M+Na]+), which supports the presence of acyl peroxide intermediate of (47) (Scheme 8.) 
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Scheme 7. Syntheses of heptafulvenes by Aumüller et al. 
 
 
Scheme 8. Proposed reaction mechanism of mCPBA oxidation of heptafulvenes to tropones. 
  For R1 and R2, see Scheme 7. 
2.1.2 Synthesis of six-membered rings by the Diels-Alder reaction 
The Diels-Alder (D-A) reaction belongs to a larger class of thermal pericyclic reactions. It 
is a concerted 6?-electron process where conjugated diene and dienophile react in [4? + 2?] 
manner, providing several pathways toward the construction of substituted six-membered 
rings with a high degree of regio-, diastereo- and enantioselectivity. Since its discovery in 
1928 (Scheme 9), the Diels-Alder reaction is one of the most important and powerful 
carbon-carbon bond-forming reactions in synthetic organic chemistry.34 The authors Otto 
Diels  and  Kurt  Alder  soon  anticipated  the  importance  of  this  discovery,  particularly  as  it  
was applied to natural product synthesis: “Thus it appears to us that the possibility of 
synthesis of complex compounds related to, or identical with, natural products such as 
terpenes, sesquiterpenes, perhaps even alkaloids, has been moved to the near prospect.” 
Diels and Alder were awarded the Nobel Prize in Chemistry in 1950 for their work on the 
reaction. 
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Scheme 9.  The original Diels-Alder reaction reported by Otto Diels and Kurt Alder in 1928. 
2.1.2.1 Diels-Alder reactions on solution-phase 
Dienes 
 
The diene component in the Diels-Alder reaction can be open-chain or cyclic with a large 
variety of different substituents. Heteroatom(s) can be incorporated into the diene moiety so 
that the scope of the reaction can be widened for the construction of six-membered 
heterocyclic compounds.35 The  diene  must  be  able  to  exist  in  the  s-cis conformation. 
Butadiene for  example  normally  prefers  the  s-trans conformation due to its energy 
minimization. In case of substituents larger than hydrogen, steric hindrance may influence 
the relative stabilities of the conformations. For simple cases, the barrier to rotation around 
the central bond is small, and rotation to the less favorable but reactive s-cis conformation is 
rapid.  
   Cyclic dienes that are permanently in the s-cis conformation are more reactive in the 
Diels-Alder reactions due to rigid cisoid conformation. Among the cyclic dienes, 
cyclopentadiene (49)  is  the  most  reactive  and  undergoes  self  dimerization  at  room  
temperature. In a [4+2] cycloaddition with p-benzoquinone (50) it gives bridged tricyclic 
adduct (51), as reported by Diels and Alder in 1928 (Scheme 9).34 Cyclic dienes being 
permanently in the s-trans conformation cannot adopt the cisoid conformation and therefore 
will not participate in the D-A reaction at all.36,37  
Unstable dienes, such as ortho-quinodimethanes, are reactive and versatile intermediates, 
which have been utilized as four-carbon units38,39 in the [4+2] cycloaddition for the 
construction of natural compounds. Early examples of this strategy were reported by 
Nicolaou40 and Vollhardt41 in an intramolecular context, where o-quinodimethanes (52) 
generated in situ from  sulfolene  precursor  (53), by cheletropic elimination of SO2 or  by 
conrotatory thermal ring-opening of benzocyclobutane (54),  gave  œstratrienone  (55) and 
estrone (56) as single diastereomers and in high yields (Scheme 10).  
The use of such an unstable diene is advantageous in that the products will contain newly 
formed aromatic six-membered rings. Polycyclic aromatic hydrocarbons can similarly 
participate in the D-A reaction. For example, anthracene (57) and its derivatives behave as a 
diene  at  sites  C9  and  C10  (Scheme  12),  where  the  lowest  (calculational)  benzenoid  
character is resided.35  
Among the heterodienes 1- and 2-aza-1,3-butadienes are the most widely studied and are 
useful for the construction of tetrahydropyridine derivatives. Pyrones and pyridines,42 with 
some aromatic character, are suitable dienes in the D-A reaction yielding aromatic products 
after extrusion of the heteroatom bridge (retro D-A reaction). 
 
 
19 
 
 
Scheme 10.  Examples of in situ generated o-quinodimethanes in the synthesis of steroidal 
  skeleton: œstratrienone (55)40 and estrone (56).41 
Inverse electron demand D-A reactions 
 
Many nitrogen containing heteroaromatic compounds are electron deficient and participate 
in the inverse electron demand Diels-Alder (IEDDA)43,44 reactions with electron rich 
dienophiles (e.g. acetals, enol ethers, enamines). In a commercial synthesis of pyridoxine 
(vitamin B6, 58) the IEDDA between oxazole diene (59) and acetal (60) provides tricyclic 
intermediate (61) (Scheme 11). The subsequent fragmentation, elimination (HCN), and 
acid-catalyzed deprotection finally gives the aromatic pyridoxine cycloadduct (58).43  
Scheme 11. Inverse electron demand D-A reactions in synthesis of functionalized pyridines. 
Heteroaromatic azadienes with multiple nitrogen atoms, such as 1,3,5-triazines and 1,2,4,5-
tetrazines are effective dienes in the IEDDA reaction and highly useful for the construction 
of diversely substituted six-membered nitrogen heterocycles, such as pyridines.43,44 An 
example of this strategy is utilized in the synthesis of new optically active analogs of (–)-
nicotine,45 where a tandem inverse electron demand Diels-Alder sequence with a 
trifluoromethyl-activated tetrazine (62) and proline-derived heterodienophilic imidate (63) 
produce 1,2,4-triazine cycloaddition product (64)  after  elimination  of  methanol  and  
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dinitrogen (Scheme 11, (S)-enantiomers shown). The diazadiene system in (64) is electron 
deficient and efficiently undergoes the second IEDDA [4+2]-cycloaddition with electron 
rich dienophiles such as enol ethers and enamines. TMSI (trimethylsilyl iodide) mediated 
removal of the protecting group (CHCl3, ?), and methylation of the subsequent nornicotines 
(HCO2H, CH2O, ?) finally yields pyridine-modified nicotine analogs (65, 66a–b) in high 
yields. 
Dienophiles 
The dienophile in the Diels-Alder reaction is generally an alkene or an alkyne bearing 
electron withdrawing functional groups. In the normal Diels-Alder reaction, the reactivity of 
the dienophile is increased by the presence of electron withdrawing substituents, such as 
formyl, ester, keto, nitro and nitrile groups conjugated to the alkene C=C double bond. 
Diels-Alder reactions can be promoted by different factors,46 such as the use of high 
pressure, and most popularly the use of Lewis acids (e.g. AlCl3), which coordinate to the 
dienophile’s heteroatom bearing a lone pair of electrons such as carbonyl oxygen. Isolated 
triple bonds, such as those in acetylene, do not readily take part in the Diels-Alder reactions. 
However, cyclic alkynes47 such as benzyne (67)48 are extremely reactive species in the D-A 
reaction with a variety of dienes due to the strained triple bond. This is illustrated in the 
synthesis of triptycene (68)49 (Scheme 12), which is incorporated in many organic 
compounds as a molecular scaffold, and has found application, for instance, in molecular 
motors.50 Cyclopropenes51 are also excellent dienophiles due to the high reactivity caused 
by a large angle strain, and ability to donate a three-carbon unit to form the cycloadduct.  
 
Scheme 12.   Synthesis of triptycene (68) by the Diels-Alder reaction with p-benzoquinone (50) 
  and benzyne (67) as dienophiles by Bartlett49 and Wittig,52 respectively. 
Heteroatom-containing dienophiles53 are commonly used for the Diels–Alder reactions and 
are valuable tools for the synthesis of biologically important heterocyclic and natural 
compounds, such as various alkaloids and pyranoids. In fact, one of the first examples of a 
hetero Diels-Alder reaction was disclosed by Alder himself in 1943, when he discovered 
serendipitously that an imine tautomer could engage appropriate dienes in a productive 
[4+2] cycloaddition.54 In a similar manner, carbonyl groups can be used as dienophiles in 
the oxo Diels-Alder reaction. Amidines and imidates are electron-rich C=N dienophiles 
participating in the IEDDA reaction as seen in the previous example (Scheme 11). 1,2,4-
Triazole-3,5-diones, and other carbonylazo compounds, are known to be powerful 
dienophiles in [4+2] cycloaddition reactions.55,56 The lower LUMO energy of the N=N 
bond, in contrast to the corresponding C=C bond in alkenes57 allows reactions to proceed 
more rapidly and often at ambient temperatures. 
Cis principle 
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The relative stereochemical outcome of the Diels-Alder reaction can be predicted on the 
basis  of  the  empirical  rule  formulated  by  Alder  and  Stein  in  1937,  known  as  the  cis 
principle.58 This  means  that  if  a  cis-dienophile is reacted, both of the cis-substituents will 
end  up  on  same  side  (face)  of  the  product.  When  a  trans-dienophile is used, both of the 
substituents will end up on different sides of the product. The same principle applies to 
dienes. Trans, trans 1,4-disubstituted dienes will end up on same side of the ring being cis 
relative to each other, whereas the cis, trans isomer of the dienes gives adducts where the 
1,4-substituents will be oriented towards different faces of the ring.59 
Endo approach 
The substituents of the dienophile can be either endo or exo in the product, depending upon 
the orientation of the diene and dienophile with each other in the transition state. The 
substituents on the dienophile can be down towards the diene (endo approach) or up away 
from the diene (exo approach). Based on the stereochemistry of a large number of Diels-
Alder reactions, Alder formulated an empirical rule known as endo addition  rule.58,60 
According to this rule, the most stable transition state results, when a maximum 
accumulation of unsaturated centers of the diene and dienophile overlap. Such an overlap is 
known as a secondary orbital interaction and will lead to energetically more favorable endo 
transition state with a 3 kcal-1 mol difference to the exo transition state, sufficient enough to 
tip the scale in favor of the endo product.61    
   An  example  of  endo selective D-A reaction where the power of strategies to exert 
stereochemical control is reflected in the total synthesis of the plant hormone gibberellic 
acid  (69)  by  Corey  et al.62 The initial chemo- and regioselective Diels-Alder reaction 
between diene (70) and quinone (71) leads to cis-decalin (72) as a single diastereomer in 
excellent yield via endo transition-state  (Scheme  13).  The  subsequent  elaboration  to  (73) 
enabled a substrate-controlled intramolecular Diels-Alder reaction, which proceeded with 
selective formation of the expected product (74). Further modification of tetracyclic 
intermediate (84) produced gibberellic acid (69).  
Scheme 13.  Use of both inter- and intramolecular Diels-Alder reactions in the stereocontrolled 
  synthesis of gibberellic acid (69) by Corey et al.62 
The outcome of the Diels-Alder reaction in these intramolecular instances is generally 
predictable based on the stereochemical requirements of the resident set of functionalities. 
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However, the use of high temperature and extended reaction time can lead to a formation of 
a thermodynamically more favorable exo product due to the reversible nature of Diels-Alder 
with elevated temperatures.61 
Regioselectivity 
When the Diels-Alder reaction takes place between an unsymmetrical diene and a 
unsymmetrical dienophile, a formation of mixtures of regioisomers is possible. Dienes with 
a substituent on the 1-position can give 1,2- (ortho)  and  1,3-  (meta) disubstituted adduct. 
When the substituent is  on the 2-position,  a mixture of 1,3- and 1,4- (para) adduct can be 
formed, however, the Diels-Alder reaction gives ortho and para adducts predominately over 
meta adducts (an example of 1,2-adduct for compound (72). This observed high 
regioselectivity  can  be  explained  by  frontier  orbital  theory,  and  by  the  coefficients  of  the  
frontier orbitals of the diene and dienophile.63 
2.1.2.2 Diels-Alder reactions on solid-phase 
Originally developed for a peptide synthesis, Merrifield64 introduced solid-phase synthesis 
of a tetrapeptide in 1963. He was later awarded the Nobel Prize in chemistry in 1984 for the 
significance and novelty of the method. Solid-phase methods were used first in peptide 
synthesis where the high efficiency of the method was demonstrated. Later in the 1970s, the 
method was applied to the synthesis of small organic compounds for the first time. During 
the 1990s, the development of solid-phase organic chemistry progressed rapidly and 
numerous novel solid-phase synthesis methods were utilized in combinatorial 
chemistry.65,66,67 In addition, the first total syntheses of complex natural products, such as 
epothilone68 and sarcodictyin,69 were performed on solid support.  
The Diels-Alder reactions have been conducted with either the dienophile or the diene 
linked to the support. The reaction conditions and the regio- and stereoselectivities observed 
are similar to those in solution. Therefore, it is not surprising that several examples of solid-
phase Diels-Alder reactions were reported in the literature, including classical 
intermolecular, inverse electron demand, hetero- and intramolecular Diels-Alder reactions 
performed on polymeric support.70 Two selected examples of D-A reactions conducted on 
solid-phase are presented below. 
 
Sun and Murray71 investigated several solid-phase Diels-Alder reactions of amino acid 
trienes in intramolecular context. These reactions gave highly functionalized hydroisoindole 
derivatives. The polymer-bound triene (75) participates in the intramolecular Diels-Alder 
reaction in CH2Cl2 at ambient temperature to give resin-bound cycloadduct (76) (Scheme 
14). The product (77) was obtained as a carboxylic acid in 48% yield after trifluoroacetic 
acid-mediated ester cleavage from the resin. In similar fashion, the intramolecular [4+2] 
cycloaddition of the triene (78) in CH2Cl2 at room temperature gives the cycloadduct (79) 
as a single reaction product in 55% yield. According to the authors, the diastereoselectivity 
of the solid-phase cycloaddition reactions resembles that of the corresponding solution-
phase reactions. The favored reaction pathway traverses through the endo transition-state, 
and the steric bulk of the ?-substituent (R1 = Bn) affects the 1,3-allylic interaction of the  
dienophilic part of the triene. 
 The same authors studied the intramolecular solid-phase Diels–Alder reaction of trienes 
containing a furan ring moiety, which has been found to be a useful auxiliary in the 
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synthesis of functionalized heterocyclic compounds. The resin-bound furoic amide triene 
(80) underwent the intramolecular Diels-Alder reaction at room temperature to produce the 
epoxyhydroisoindoline (81) in 55% yield (Scheme 14). A furfuryl group was also tested for 
the intramolecular Diels-Alder reactions. The isopropyl-substituted triene (82), with an N-
benzoyl tertiary amine, participated in the [4+2]-cyclization reaction that was carried out in 
CH2Cl2 for 60 h. The product (83) was isolated as a single isomer in 65% yield, being the 
highest of the entire series. 
 
 
Scheme 14.  A series of intramolecular Diels-Alder cycloadditions studied on solid-phase. 
 
All of the intramolecular cycloaddition reactions of furan-substituted trienes studied 
followed the endo route.71 Finally, Sun and Murray investigated the solid-phase 
intramolecular Diels-Alder reaction of the vinylfuran derivative (84) (Scheme 14).71 The 
reaction of triene (84) went to completion in CH2Cl2 at room temperature for 2 days. The 
intramolecular Diels-Alder reaction was followed by a rearrangement process where the 
aromaticity  of  the  furan  ring  was  restored.  The  trans-fused tricyclic product (85) was 
obtained in 37% yield 
 
Compound libraries based on the decalin-scaffold occurring in numerous natural products 
have yielded novel and potent inhibitors of several tyrosine kinases such as VEGFR-2 
(vascular endothelial growth factor receptor 2), reported by the group of Waldmann.72,73 
Recently, the authors reported a traceless synthesis of a functionalized decalin scaffold on 
solid support, including a diversity generating cleavage.74 The 5-thiazole linker was 
immobilized on a polymeric support (Rink amide) and the polymer-bound diethyl 
phosphonate (86) was used in the Horner-Wadsworth-Emmons olefination with 
methacrolein and LiHMDS (lithium hexamethyldisilazide) as a base to give the polymer-
bound diene (87) (Scheme 15). The subsequent Diels-Alder reaction, with 2-
methoxycarbonyl cyclohexenone as a dienophile and Sc(OTf)3 as  a  Lewis  acid  catalyst,  
gave the desired polymer-supported cis-1,2-dehydrodecalin derivative (88) with full 
conversion (by NMR) after TFA release from resin (Scheme 15).  
The allylic position of the 5-thiotetrazole linker allowed an elegant diversity-generating 
cleavage by metal-assisted nucleophilic reactions. Employing Pd(0), Cu(I), and Ag(I) 
reagents significantly extended the scope of the linker system and the released 
functionalized cis-decalins (89–91) (Scheme 15).74 Interestingly, the use of palladium led to 
the replacement with stereochemical net retention (double inversion) of the 5-thiotetrazole 
moiety, when phenylsulfinate was employed in compound (91). 
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Scheme 15.  Synthesis of cis-decalin (88) on solid support and subsequent diversity generating 
  cleavage by metal catalysis. 
 
Since its discovery, the Diels-Alder reaction has been the most widely used synthetic tool in 
organic chemistry. Many modifications have been developed, such as inverse electron 
demand,43,44 hetero,43,53,75 intramolecular76,77,78 and asymmetric79,80,81,82,83,84,85 Diels-Alder 
reactions. Control of both diastereoselectivity and enantioselectivity is very important in the 
field of total synthesis, where the use of the D-A reaction has afforded numerous solutions 
and applications in the construction of natural products.86 Nature's repertoire of biosynthetic 
transformations has been recognized to include the biosynthetic Diels-Alder cycloaddition 
reactions including five isolated and purified enzymes thus far, that are consistent in the 
catalysis of the Diels-Alder reaction.87,88,89,90,91 
2.2 Protein kinases 
Protein kinases, known also as phosphotransferases, are key regulators of cell function that 
constitute  one  of  the  largest  and  most  functionally  diverse  gene  families.  By  adding  
phosphate groups to substrate proteins, protein phosphorylation plays a significant role in a 
wide range of cellular processes. The human genome contains 518 protein kinase genes and 
they constitute about 2% of all human genes.92 Up to 30% of all human proteins may be 
modified by kinase activity, and protein kinases are known to mediate most of the signal 
transduction in eukaryotic cells by modification of substrate activity. Protein kinases also 
control many other cellular processes, including metabolism, transcription, cell cycle 
progression, cytoskeletal rearrangement, cell movement, apoptosis, and differentiation. 
Since protein kinases have profound effects on a cell, their activity is highly regulated. 
Kinases are turned on or off by phosphorylation (sometimes by the kinase itself by 
autophosphorylation), by binding of activator proteins, inhibitor proteins, or small 
molecules, or by controlling their location in the cell relative to their substrates. Protein 
kinases are seen as potential therapeutic targets since mutations and dysregulation of protein 
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kinases play causal roles in multiple human diseases, affording the possibility of developing 
modulators (inhibitors) of these enzymes for use in disease therapy.93,94,95   
2.2.1 Protein kinase inhibitors  
Background – the discovery of staurosporine 
 
The importance of protein phosphorylation became known more than 30 years ago when the 
first connections between abnormal protein phosphorylation and disease also became 
evident.96 In 1981, Nishizuka and his colleagues discovered that tumor-promoting phorbol 
esters (92) were potent activators of protein kinase C (PKC).97 The first protein-kinase 
inhibitors were developed in the early 1980s based on the discovery of isoquinoline 
sulphonamides, which showed inhibition of cyclic nucleotide-dependent protein kinase and 
protein kinase C. One of the compounds, fasudil hydrochloride,98 progressed to human 
clinical trials and was approved for the treatment of cerebral vasospasm, however being a 
non-specific inhibitor of several protein kinases.99  
In 1977 the discovery of staurosporine100 (93, antibiotic AM-2282) (Figure 1), a natural 
product fungicide produced by the bacterium Streptomyces staurosporeus, was the first of 
over 50 alkaloids to be isolated with this type of bis(indole) chemical structure and showed 
nanomolar inhibition of PKC.101 Despite the structure determination in 1978, the first total 
chemical synthesis was achieved in 1996.102 The same bacterium also produces bis(indole) 
maleimide rebeccamycin103 (94, Figure 1), with high structural similarity to staurosporine, 
but has surprisingly no affinity to protein kinases. Rebeccamycin does however carry 
significant antitumor properties in vitro by inhibiting topoisomerase I.104,105 Staurosporine 
(93) had enormous impact on the pharmaceutical industry, where it was used along with its 
derivatives in cell-based assays by hundreds of laboratories to invoke a myriad of roles for 
PKC. However, it and several other bisindolylmaleimides were later shown to lack 
specificity, since their inhibition of multiple other protein kinases in vitro as well.99 
Several staurosporine analogs have progressed to human clinical trials, despite the fact that 
it is unclear whether their efficacy overcomes the inhibition of PKC, another protein kinase, 
or the combined inhibition of several kinases. Naturally occurring 7-
hydroxystaurosporine106 (95) (Figure 1) blocks cell-cycle progression and might act by 
inhibiting the cell-cycle checkpoint-control kinase (CHK1). N-benzoylstaurosporine,107 (96) 
also known as midostaurin, is a multi-target kinase inhibitor entered in phase III clinical 
trials for treatment of acute myeloid leukemia (AML).108 Ruboxistaurin109,110 (97, 
LY333?531) belongs to a class of synthetic macrocyclic bisindolylmaleimides with a 
simplified structure, and was reported to inhibit PKC? isoform (IC50 = 4.7 nM)110 more 
potently  over  other  PKC  isoforms.  It  has  been  shown  to  normalize  the  elevated  levels  of  
PKC activity in the retina and kidneys of diabetic rats111 and is currently in phase III clinical 
trials for the treatment of diabetic microvascular disease and retinopathy.  
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Figure 1. A) Chemical structures of ATP and some ATP-competitive natural, semisynthetic 
  and synthetic bis(indole) alkaloids. B) A schematic example of ATP-binding pocket 
  in cyclin dependent protein kinase 2 (CDK2) in complex with a) ATP and b) 
  staurosporine. The green area indicates protein surface with high hydrophobicity.112 
 
The first selective protein kinase inhibitors 
 
The majority of the protein-kinase inhibitors that were developed by the end of the 1980s 
had bis(indole)alkaloid in their structures. Due to the ATP-competitive mode of action, it 
became obvious that such compounds were insufficient to compete with the high 
intracellular concentrations of ATP (98) (2–10 mM). In addition, the determination of the 
first 3D-structure of a protein kinase A (PKA)113 showed that the residues involved in ATP 
binding pocket possessed high similarity from kinase to kinase. Therefore, at that time it 
was strongly believed that it was ‘impossible’ to develop specific protein kinase inhibitors 
with the required high affinity. However, the identification of the cellular targets for 
cyclosporin A114 and FK506115 (tacrolimus) in 1991 changed that belief, since it was found 
that both of these agents were potent and specific inhibitors of calcineurin,116 a  Ca2+-
calmodulin-dependent protein kinase. 
Maybe the most important finding was related to immunosuppressant drug rapamycin117 
(98, sirolimus), which is produced by Streptomyces hygroscopicus, a soil bacterium that 
originates  from Easter  Island.  Rapamycin  was  identified  more  than  30  years  ago  and  was  
originally developed as an antifungal agent. The anticancer properties of rapamycin were 
noticed after its discovery but the mechanism of action remained unclear until the molecular 
target of rapamycin in yeast was identified to be a protein kinase, named “target of 
rapamycin” (Tor).118 The mammalian homolog mTOR was identified later. Rapamycin (98) 
was the first drug approved for clinical use that inhibited one protein kinase specifically.99 
Despite the fact that cyclosporine A, FK506, and rapamycin (98) are highly potent and 
useful compounds as immunosuppressants and anti-cancer agents, they lack one crucial 
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property – they are not orally bioavailable – therefore their medicinal use is hampered. 
 
Imatinib – first selective and orally available small molecule kinase inhibitor 
 
In the field of oncology, efforts to develop orally active drugs that target specific protein 
kinases have been extensively focused and a number of kinase inhibitors have already been 
developed and approved for cancer treatment. Some of the most promising drugs developed 
are inhibitors of protein tyrosine kinases, which have been seen as excellent targets for 
cancer chemotherapy. Imatinib119 (100) was the first member of this new class of agents by 
specifically inhibiting Abelson tyrosine kinase (ABL) and is used for treatment of chronic 
myelogenous leukemia (CML). Although imatinib is an ATP competitive inhibitor, the 
determination of the 3D structure of ABL in complex with it showed that the drug extends 
much further into the catalytic site120 and binding of imatinib induces a structural transition, 
where the kinase adopts the inactive conformation.  
Another important tyrosine kinase in the field of oncology is EGFR (epidermal growth 
factor receptor), which is overexpressed in many cancers of epithelial origin. Gefitinib 
(101),121 erlotinib121 and labatinib (102)122 are selective inhibitors of EGFR with a common 
4-anilinoquinazoline structure, used in clinics against a variety of cancers. The second 
generation inhibitors of tyrosine kinases such as neratinib (103),123 are able to irreversibly 
inhibit  Her2/neu  (human  epidermal  growth  factor  receptor  2)  and  EGFR  kinases,  and  are  
currently being used in human clinical trials.  
 
 
 
While the protein kinase inhibitors have shown their efficiency in the treatment of various 
cancers, the long-term side effects are not known. Resistance can also be an issue since 
many patients who were treated with imatinib have become resistant, due to mutations in 
Abl. Therefore, kinase inhibitors might be most effective if administered in combination.95 
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2.2.2 Protein kinase C 
The protein kinase C (PKC) family of serine/threonine protein kinases includes at least ten 
mammalian isoforms124 that are involved in intracellular signal transduction cascades and in 
cellular events such as proliferation, differentiation and apoptosis.125,126 The PKC family 
can be divided into three subgroups according to their structures and activation 
mechanisms.124 Classical/conventional PKCs (cPKCs: ?, ?I, ?II, and ?) require calcium and 
diacylglycerol (DAG, 104) (Figure 2) for activation, whereas novel PKCs (nPKCs: ?, ?, ?, 
and ?) need only endogenous DAG for activation. In contrast to cPKCs and nPKCs, 
atypical PKCs (aPKCs: ?, ???) require neither calcium nor DAG for activation. Only the 
regulatory C1 domains of cPKCs and nPKCs are capable of binding DAG and tumor-
promoting phorbol esters (92) (Figure 2), leading to enzyme activation.97 Aberrant signaling 
through PKC isoforms and other C1 domain containing proteins has been correlated to a 
number of human ailments, including neurological diseases;127 especially Alzheimer’s 
disease,128,129,130 immunological131,132 in addition to cardiovascular133,134,135 diseases and 
cancer.136,137,138 Therefore, PKC and other C1 domain-containing proteins have been 
subjects of intensive research and drug development.139  
 
Structure, function and regulation 
 
The structure of all PKCs consists of a regulatory domain and a catalytic domain tethered 
by a proteolytically labile hinge region. The C-terminal catalytic domain is highly 
conserved  among  all  the  different  isoforms,  whereas  the  N-terminal  regulatory  domain  is  
less consistent.124 The amino terminus of the PKCs contain several shared subregions. 
Diacylglycerol (104)  is  a  pivotal  lipid  second  messenger  and  a  natural  agonist  of  the  C1  
domain which is present in all of the isoforms of PKC. The phorbol esters (92) (Figure 2) 
are shown to bind similarly as DAG to the C1 domain. However, in atypical PKCs, the C1 
domain is incapable of binding neither DAG nor phorbol esters. The Ca2+-binding C2 
domain can be found in the regulatory part of conventional and novel isoforms, but is 
functional as a Ca2+ sensor only in the cPKCs. Extensive biochemical studies have 
established that protein kinase C is allosterically regulated by its pseudosubstrate.124,140 This 
small oligopeptide mimics the substrate and binds in the substrate-binding cavity in the 
catalytic domain, thus keeping the enzyme inactive.  
The PKCs are non-receptor kinases, which in the inactive conformation can be found in 
the cytoplasm of cells.125 When calcium and DAG are present in sufficient concentrations, 
they bind to the C2 and C1 domain, respectively, enabling PKC to localize into various 
membranes.141,142 Actually, the isoform-specific effects on cells are a result of the different 
subcellular localizations of the isoforms of PKC.143,144 The interaction with the membrane 
induces the conformational change of the enzyme causing the pseudosubstrate to move out 
from the ATP-binding site.125 The conformational change of the enzyme reveals the  hinge 
region which becomes proteolytically labile and if cleaved, reveals the essential kinase 
domain.124  
The catalytic domain of protein kinase C has approximately 40% amino acid identity 
with PKA.124 Molecular modeling based on the solved structure of protein kinase A113 has 
been useful in identifying surface-exposed residues.144 The residues involved in both 
catalysis and maintenance of the fold of the kinase domain, are conserved, with differences 
in residues found primarily on the surface of the protein. The conventional and novel PKCs 
have three phosphorylation sites; the activation loop, the turn motif, and the hydrophobic 
motif. The atypical PKCs are phosphorylated only on the activation loop and the turn motif. 
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These phosphorylation events are essential for the activity of the enzyme and for its correct 
intracellular localization.124 3-Phosphoinositide-dependent protein kinase-1 (PDK-1)124,145 is 
the upstream kinase for all protein kinase C isoforms and is responsible for initiating the 
process by transphosphorylation of the activation loop.146  
 
The C1 domain of PKC 
 
In conventional and novel PKCs the regulatory part contains two DAG-/ phorbol-binding 
C1 domains, named C1a and C1b.124,147 Atypical protein kinase C’s contain a single copy of 
the  domain  and  are  not  able  to  bind  phorbol  esters.  The  crystal  structure  available  for  C1 
domain was determined for PKC? complexed with phorbol 13-O-acetate by Zhang et al. in 
1995 (Figure 2b).148 In  addition,  the  crystal  structure  of  the  full-length  ?II  isoform  of  
protein kinase C was published in 2011.149 Crystal  and  NMR150 structures have revealed 
that C1 domain is Cys-rich region of approximately 50-residue long sequence containing 
two zinc finger structures, where the Zn2+ ions are coordinated by His and Cys residues at 
opposite ends of the primary sequence, helping to stabilize the domain. Elucidation of the 
structure of the C1b domain of PKC? in the presence and absence of bound phorbol acetate 
unveiled the mechanism of how ligand binding recruits the C1 domain to be partly buried in 
the membrane.148,151 Binding of the ligand does not result in any significant conformational 
change in the domain. However, it dramatically alters the surface properties of the polar 
groove, where the ligand acts as a cap on the top part of the domain to produce a continuous 
hydrophobic surface and thus masking the polar groove for membrane interaction.149 It 
should be mentioned that many proteins unrelated to protein kinase C contain typical or 
atypical C1 domains, capable of binding phorbol esters.152 
 
DAG (104) R1, R2 = OH (phorbol, 105)
R1, R2 = OCOR (phorbol esters, 92)
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Figure 2. A) Structures of 1,2-diacylglycerol (DAG, 104), phorbol (105) and phorbol esters 
 (92). B) The crystal structure of the PKC? C1b domain complexed with phorbol 13-
 O-acetate (ball and stick representation) (2.2 Å resolution, PDB ID: 1PTR).149 Top 
view of the binding pocket  of the crystal structure. The surface is colored as: 
oxygen atoms (yellow), nitrogen atoms (blue), carbon atoms (green) and rest of the 
C1b surface is colored (green). The figure is created with ICM-Browser (version 
 3.7-2a, MolSoft L.L.C.). 
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The C1-domain as a target for natural and synthetic compounds 
 
As discussed earlier, the high intracellular concentrations of ATP together with the 
consistent structure of the catalytic site among protein kinases sets limits for the 
development of protein kinase inhibitors for clinical use with a high risk of producing side 
effects.153 Since  many protein  kinases  such  as  PKA and PKC have  regulatory  domains  as  
part of their structure, however, another strategy to modify protein kinase activity presents 
itself. The PKC regulatory domain, C1, is unique to PKC and found only in a small number 
of kinases, offering a selectivity advantage, making the C1-domain an attractive drug 
target.154 Such kinase inhibitor would probably have specificity for PKCs over other kinases 
and it would enable the possibilty to discover PKC isozyme selective inhibitors. In addition, 
unlike agents that binds to the ATP binding site thereby inhibiting kinase function, C1 
domain binders could inhibit or activate kinase activity.155 A number of natural compounds 
targeting the C1 domain of PKC have been discovered.  Some of them will be presented as 
examples here together with some simplified synthetic analogs.  
 
Bryostatins 
 
The bryostatins are a group of 20 macrolide lactones first isolated from the marine bryozoan 
Bugula neritina in 1968 followed by the elucidation of the structure of bryostatin 1 (106) 
(Figure 3) in 1982.156 It has been established that the true source of the bryostatins is not 
actually bryozoans but rather its bacterial symbiont.157 Regardless of bryostatin 1 being 
(106) a well-known natural compound, its highly complex structure featured with three 
heavily substituted pyran rings (A, B and C) with numerous stereocenters, it was nearly 30 
years before the first total synthesis of bryostatin 1 was published.158 Bryostatins (Figure 3) 
are potent modulators (activators) of protein kinase C and bind in a similar fashion to 
phorbol  esters  and  diacylglycerols  in  the  cysteine-rich  C1a  and  C1b  domains  of  PKC.159 
However,  while  the  phorbol  esters  (92)  are  tumor  promoters,  the  bryostatins  have  
antineoplastic activity. Bryostatin 1 (106) induces a rapid activation and 
autophosphorylation of PKC that results in the translocation of the PKC enzyme to the 
membrane.  Interest  in  the  bryostatins  has  been  intense  due  to  a  wide  range  of  potent  
bioactivities associated with them. The most well-studied bryostatin 1 (106) has nanomolar 
affinity (Ki 1.40 nM) for PKC?.160 It has shown activity against a range of cancers in vivo161 
and been used, therefore, in numerous clinical trials, despite its low natural abundance, 
difficult isolation,162 and structural complexity. 
 
In addition to its anticancer properties, bryostatin 1 (106) has been shown to synergize the 
effects of other antineoplastic agents,163,164 and is active against conditions, such as stroke165 
and diabetes.166 Unlike most antineoplastic agents, it also stimulates the immune system.167 
Bryostatin improves learning and extends memory in animal models,168,169 serving as a 
significant lead for treatment of cognitive dysfunctions, including Alzheimer's disease.170 
The development of new methods to produce bryostatin has received much focus, due to its 
low natural abundance. Mendola and his colleagues have developed an efficient in-sea 
aquaculture method for producing Bugula neritina, capable of providing 100–200 g of 
bryostatin 1 annually.171 The group of Haygood, in tandem, have discovered the Bry genes, 
and is attempting to transfect these genes into other bacteria.161 
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Figure 3. Some members of natural bryostatin macrolide lactones. 
 
 
Bryostatin analogs 
 
Since the total syntheses of bryostatins require generally over 40 linear steps,172,173 
substantial interest in the synthesis of simplified analog structures has emerged.172 Wender 
et al. have developed synthetic routes to stripped derivatives of bryostatins for 25 years by 
reducing the number of synthetic steps.174,175,176 Among  the  first  members  of  biologically  
active synthetic bryostatins, analog (107a)174 (Figure 4), bearing B-ring cyclic acetal 
construction and several other structural simplifications (stripped A and B rings, lack of 7-
OAc, 8-dimethyl and 9-OH groups, and absence of B-ring C13 olefin substituent), was 
reported to show in vitro activity comparable to that of bryostatin 1 (bryostatin 1: Ki = 1.35 
nM; (107a): Ki = 3.4 nM).174 The same authors proved that the secondary hydroxy at C3 of 
(107a) (Figure 4) is essential for the correct orientation of the macrocycle and thus for the 
high affinity.174When the methyl substituent at C26 of compound (107a) was replaced with 
a hydrogen atom, compound (107b, picolog)176 was reported to be 100-fold more potent 
than bryostatin 1 at inhibiting the growth of numerous human cancer cell lines and showed 
promise in treating mice with leukemia.176 
 
Another group of important synthetic bryostatin derivatives introduced by the Keck group, 
are so-called Merles, which bear the same structural feature of A, B-ring bipyran 
construction, found in natural bryostatins (Figure 4).177,178 For example, the three reported 
that analogs with C7,13 exo-methylene substituents on both A- and B-rings (108a–c) have 
higher affinity for PKC? than bryostatin 1 (106). The same authors reported preparation of 
simplified analogs around both A- and B-rings. Despite high structural similarity to 
bryostatins, the derivatives with a simplified A-ring interestingly did not behave like 
bryostatins but rather like tumor-promoting phorbol esters (92).179,180 However, Keck’s 
compound (109, Merle 28)180 (Figure 4) bearing the critical residues of the C7–C9 region 
around the A-ring has antiproliferative properties that are similar to the natural bryostatin 1. 
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Figure 4. Synthetic derivatives of bryostatins. Ki values for PKC? in brackets. 
 
Bistramides 
 
The discovery of a novel marine metabolite from ascidian Lissoclinum bistratum in New 
Caledonia, named bistramide A (110) (bistratene A) was reported by Verbist et al. in 
1988,181 followed by the isolation of four additional members (bistramide B–D, K) of the 
family four years later.182 In 2004, the Kozmin group reported the total synthesis of 
bistramide A (110), with complete assignment of the stereochemistry.183 Bistramide A was 
initially found to possess potent cytotoxic184 and neurotoxic185,186 properties and with 
profound impact on cell cycle regulation, leading to growth arrest, differentiation, and 
apoptosis in several cell lines.187,188 Subsequent studies revealed that bistramide A induced 
highly selective activation of a single PKC isotype ?.189 However,  bistramide  A  (110) 
shows only micromolar affinity against PKC? (Ki =  28  ?M),  thus  is  not  very  potent.  The  
primary  cellular  receptor  for  bistramide  A  was  described  to  be  actin,  by  Statsuk  et al. in 
2005.188 In addition, it is reported that bistramide A (110) does not activate PKC? in vitro 
and either does it compete with phorbol esters in the C1 domain.188,190,191 While bistramide 
A failed to translocate green fluorescent protein (GFP)-PKC? in rat basophilic leukemia 
(RBL) cells,188 the immunostaining and fractionation studies showed migration of PKC? to 
the perinuclear region rather than nuclear or plasma membrane.189 In addition, only specific 
substrates were shown to be phosphorylated in the presence of (110),  and  therefore  it  is  
discussed to be a result of a plausible atypical mode of activation.192 
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Ingenols 
 
Isolated in 1968 by Hecker,193 ingenol  (111) (Figure 5) belongs to a group of naturally 
occurring ingenane diterpenes that possess the same bicyclo[4.4.1]undecane ring system 
with variation in peripheral functionalities.194 Compared to structurally closely related 
phorbol (105), ingenol (111) is more lipophilic and shows micromolar affinity to PKC (Ki 
values 10 mM and 30 ?M, respectively). Ingenol esters, like ingenol 3-hexadecanoate 
(112)193,195 and ingenol 3-tetradecanoate (semisynthetic, 113)196 (Figure 5), are however 
highly potent tumor promoters and powerful activators of PKC.197 Since the early 1980s, 
numerous attempts have been made to synthetically reproduce the combination of important 
biological function and challenging complex architecture,198 leading finally to the total 
synthesis of ingenol (111), published by Winkler et al. in 2002.199 The  importance  of  the  
indispensable trans bridgehead or in–out stereochemistry of the ingenol core is clear since 
the thermodynamically less strained and more stable C8 epimeric (out-out) isoingenol 
analog  (114, Figure 5),200 having the fully elaborated AB-ring, completely lacks the 
biological activity related to ingenol esters. 
Ingenols can be extracted from the sap of Euphorbia peplus L., and used in traditional 
medicine to treat  conditions such as skin tumors,  migraines and parasites.  In addition, the 
ingenanes display interesting biological profiles that range from tumor-promoting, to anti-
leukemic, and anti-HIV activities.201 Ingenol angelate, or PEP005 (115) (Figure 5), is a 
selective activator of the classical and novel PKC isoenzymes and has both anti-cancer and 
proinflammatory effects, and has shown promising results in the treatment of skin 
tumors.202,203 Naturally occuring C20-acetylingenol angelate (PEP008, 116) (Figure 5), was 
recently reported to arrest the growth of solid tumors derived from breast cancer, colon 
cancer, and melanoma cell lines in vitro.204  
 
Figure 5.  Natural ingenol diterpenoids and examples of synthetic derivatives. 
 
The polyhydroxylated southern region plays a key role in the biological activity of 
ingenoids.205 The  apoptotic  activity  of  ingenol  (111), ingenol dibenzoate206 (IDB, 117, 
Figure 5) and various C3, C5, and C20 analogs was investigated in the leukaemia Jurkat-
cell line by Blanco-Molina et al.201 The authors reported that esterification of the 20-
hydroxy was required to induce apoptosis, while a free 5-hydroxy was critical for PKC 
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activation. The dibenzoate (117) induced apoptosis in a dose-dependent manner, however 
not via a PKC-mediated bathway, but via caspase-3 activation.203 In contrast, ingenol itself 
(111) did not induce significant apoptosis even at the higher doses. 
Winkler et al.207 reported the synthesis of simplified ingenol analogs with the same in-
out stereochemistry (Figure 5) as found in natural ingenols. While the C3,20-dibenzoyl 
compound (118a)  was  found  to  be  inactive  for  PKC?, the 3-monobenzoate derivative 
(118b) showed micromolar affinity with a Ki of 0.17 ?M.207 The same authors hypothesized 
that loss of the C20 ester of ingenol might occur in vivo, giving the more active monoester.  
 
Summary of the natural and synthetic compounds targeting the C1 domain  
 
Though compounds binding to C1 domain can be obtained from natural sources, the 
isolated yields are usually very low with a need to be harvested from sensitive ecosystems, 
such as seas and oceans. In addition, the compounds often have highly complex structures 
and therefore the total syntheses of the compounds are laborious. However, studies with 
these compounds have yielded valuable pharmacophores, which have been used to develop 
simplified analogs of the natural compounds, such as those found in synthetic bryostatin 
(107–109), for example. 
While the biological potential of synthetic ingenols has been somehow disappointing, the 
discovery of new naturally occurring ingenols is encouraging. Ingenol angelate (PEP005, 
115) has been shown to be a potential treatment of skin tumors and PEP008 (116), another 
naturally occurring ingenol derivative, has only recently been reported to arrest the growth 
of a variety of solid tumors in vitro. A comprehensive review on recent developments in the 
C1 domain targeting compounds has been published recently.139 
2.2.3 Pim kinases 
The three Pim family members (Pim-1, Pim-2 and Pim-3) form an evolutionary distinct 
subgroup of serine/threonine-specific kinases belonging to the group of calcium/calmodulin 
-dependent (CAMK) protein kinases. The name Pim refers to the original identification of 
the pim-1 gene in 1984 as a frequent proviral insertion site in Moloney murine leukemia 
virus-induced T-cell lymphomas.208 Pim kinases are highly homologous to each other and 
have partially overlapping functions and expression patterns.209 Interestingly, unlike most 
other protein kinases, Pim kinases are unusual since they are kept in a constitutively active 
conformation,210 thus the enzymatic activity in a cell is dependent on the absolute amount of 
protein present. In hematopoietic cells, expression of Pim kinases is stimulated by 
numerous growth factors and cytokines such as interleukins.211 When overexpressed, Pim 
kinases are oncogenic and have been implicated both in hematopoietic malignancies such as 
leukemias and lymphomas212 and  in  numerous  solid  tumors  such  as  prostate,  colon,  oral,  
hepatic and pancreatic cancers.213,214,215 Pim-1, -2 and -3 deficient mice have been generated 
and, while viable and fertile, have shown reduced body size and impairment of proliferation 
of hematopoietic cells in response to growth factors.209 
Pim kinases promote tumorigenesis by supporting cell survival216 and by enhancing 
resistance of cancer cells against chemotherapy217 and radiation therapy.218 Pim-1 is able to 
interact and phosphorylate several targets that are involved in cell cycle progression or 
apoptosis. Pim-1 can inhibit apoptosis through interactions with the anti-apoptotic 
molecules, bcl-2 (B-cell lymphoma 2) and Gfi-1 (growth factor independent 1 transcription 
repressor).211 In addition, all Pim family members phosphorylate and thereby inactivate the 
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pro-apoptotic BAD protein reported by several groups.219,220,221 This may explain why Pim 
kinases so efficiently cooperate with MYC (v-myc myelocytomatosis viral oncogene 
homolog) family transcription factors in the development of lymphoid or solid tumors. Even 
though MYC-overexpressing cells proliferate faster, they are more prone to apoptosis, 
therefore, a growth advantage is given to cells that also co-overexpress Pim kinases, which 
regulate the balance between anti- and pro-apoptotic factors and boost activities of 
transcription factors, that are essential for the production of cytokines and other survival 
factors. These conclusions are supported by recent reports by Wang et al.,222,223 showing 
that Pim-1 synergizes with MYC, both to induce advanced prostate carcinoma and to 
maintain tumorigenicity of the cancer cells. Furthermore, it was recently demonstrated that 
Pim kinases increase the metastatic potential of adherent cancer cells.224 Mice lacking 
activities  of  all  the  three  Pim  kinases  are  fertile  and  show  only  minor  phenotypic  
abnormalities,209 therefore compounds selectively inhibiting Pim activity are not expected 
to have adverse side effects. For all these reasons, Pim kinases have become intriguing 
targets for cancer therapy.225 
 
The crystal structure of Pim-1 and development of Pim inhibitors 
 
Recently, the development of small molecule inhibitors against different types of protein 
kinases has enormously progressed, including compounds targeting Pim kinases.226,227 The 
potential for the development of Pim-selective inhibitors is enhanced by the crystal 
structure of Pim-1 (Figure 6)210, which was solved in 2005 by multiple groups.210,228,229  
 
 
Figure 6. Structural overview of the Pim-1 crystal structure at 2.1 Å resolution (PDB-code: 
  1XQZ).210 
The hinge region that contains the ATP binding site of Pim-1 has a novel architecture, 
containing an additional amino acid residue not found in other protein kinases. This residue 
Pro123 lacks a key amide hydrogen bond donor and therefore does not allow the formation 
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of two hydrogen bonds to ATP present typically in protein kinase ATP complexes. This 
important and unique structural feature230 offers tremendous potential as a target for the 
design of Pim-inhibitors, which do not compete against more than 500 kinases that carry a 
conserved ATP-binding site to access high intracellular levels of ATP.  
Staurosporine analogs 
Several simplified staurosporine-like compounds have been investigated as Pim inhibitors, 
including macrocyclic bis(indolyl)maleimides such as PKC? inhibitor ruboxistaurin (97). 
The potency of (97) is much weaker against both Pim-1 (IC50 = 200 nM,231 55 nM226) and 
Pim-2 (IC50 = 20 ?M) than the stronger potency staurosporine (93), (Pim-1: IC50 = 10 
nM).228 However, (97) was found to effectively induce cell death and suppress growth of 
leukemia cells.231 Another bis(indolyl)maleimide derivative (BIM-1, 119) (Figure 7), with 
simplified structure, has been described along with the crystal structure of Pim-1 to show 
low nanomolar potency (Pim-1: IC50 =  27  nM),228 thus inhibiting other kinases including  
PKC, MSK-1 (mitogen- and stress-activated protein kinase) and GSK-3 (glycogen synthase 
kinase 3).100 
     The Meggers group has described staurosporine-mimicking, ruthenium-containing, 
organometallic complexes that show high potential as protein kinase inhibitors (Figure 
7).232,233,234 In such metal complexes the coordinative bonds are kinetically inert and thus 
stable in biological environments: Thus they should behave as purely organic compounds, 
without displaying any metal-related cytotoxicities.235 Meggers et al. have previously 
reported potent, and Pim-1 selective, chiral ruthenium complexes, such as (R-120a) and (S-
120b) substituted with a cyclopentadienyl ring and the CO group to the pseudotetrahedral 
ruthenium center.232 The latter inhibits Pim-1 at concentrations more than two orders of 
magnitude lower compared to staurosporine (S-120b: IC50 = 0.22 nM; staurosporine, 93: 
IC50 = 10 nM).232 When the cyclopentadienyl ring is replaced with a tridentate 1,4,7-
trithiacyclononane  ligand,  the  racemic  octahedral  ruthenium  complex  (rac-121a)234 has 
nearly 20-fold potency for Pim-1 compared to staurosporine (93) (IC50 = 0.45 nM) but 
unfortunately also displays affinity to GSK-3? (IC50 = 100 nM). In the very recent example, 
derivative (121b)236 (Figure 7), reported with two additional hydroxy groups on the 
pyridocarbazole scaffold, has subnanomolar affinity to the Pim-1 (IC50 = 0.075 nM at 100 
?M  ATP)  and  at  the  same  time  a  selectivity  over  other  kinases,  such  as  PAK-1  (p21-
activated kinase 1) and GSK-3?, of 1093 times and 267 times, respectively.236 
 
The crystal structure of Pim-2 has been recently elucidated in a complex with 
organoruthenium complex (rac-120a).237 The structure is highly similar to Pim-1, 
particularly in the ATP pocket, which is nearly completely conserved in comparison to the 
overall sequence identity of 55%. The main structural distinction between the two kinases is 
the absence of the C-terminal ?J helix (colored in red, Figure 6) in Pim-2, which removes a 
significant stabilizing interaction close to the interface between the N and C-terminal lobes. 
The last 23 residues of Pim-2 share little sequence identity with Pim-1 and are disordered. 
The same authors reported SAR study for 14 organoruthenium complexes, where additional 
hydrogen bonding groups at the R1 and  R2 positions dramatically increase the potency 
against Pim-1 and Pim-2 kinases.237 The majority of compounds were slightly more potent 
against Pim-1 than Pim-2. The most potent inhibitor for Pim-2 (rac-120c)237 (Figure 7) 
,bearing an additional carboxyl group at the pyridine ring (R2) gave almost complete 
inhibition at a concentration of 10 nM for Pim-2, and was marginally less effective against 
Pim-1. 
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Figure 7.  Structures of BIM-1 and staurosporine-mimicking ruthenium complexes as efficient 
  kinase inhibitors. IC50 values for the inhibition of Pim-1 are given. 
Imidazo-, pyrazolo- and triazolopyridazines 
Bullock et al.228,238 were among the first to report Pim inhibitors with unusual binding 
mode. The high-resolution crystal structure of a Pim-1 inhibitor (122a) complex revealed 
that imidazo[1,2-b]pyridazines (class I, Figure 8A) binds to the opposite side of the ATP 
binding pocket and surprisingly interact with the amino terminal lobe helix ?C rather than 
with the kinase hinge region, thus represent ATP competitive but not ATP mimetic 
compounds with nanomolar potency for Pim kinases (Figure 8A).228,238 One of the reported 
compounds (122a) was highly Pim-1 selective when screened against a panel of 50 kinase 
catalytic domains. In addition, (122a) has in vitro antileukemic activity in various cell line 
models and significantly suppresses in vitro growth of leukemic blasts from AML patients 
samples.238 In 2009, SuperGen (now Astex Pharmaceuticals) developed the N-
methylpiperidine derivative (122b, SGI–1776)239 (Figure  8A)  with  a  reported  low  
nanomolar affinity for Pim-1 (IC50 = 7.0 nM). It has recently advanced to phase I clinical 
trials and therefore became the first clinical-stage investigational drug specifically targeting 
Pim kinases.239,225 Pyrazolo[1,5-a]pyrimidines (class II) such as (123) (Figure 8A), with no 
reported IC50 value, shows 10% residual Pim-1 activity at 1 ?M concentration.228   
 Triazolo[4,3-b]pyridazines (class III, structurally related to I and II) were identified as 
highly selective inhibitors of Pim-1 by Vertex Pharmaceuticals;240,241 however, the binding 
mode is different from imidazo[1,2-b]pyridazines (class I).  In  the  crystal  structure  of  
compound (124a) (Figure 8A), m-CF3-phenyl ring makes contact with the hinge Glu121 by 
way of a bifurcated hydrogen bond between the aromatic protons on C5 and C6 and the 
backbone carbonyl of Glu121 (Figure 8B).240 The poor solubility and permeability of the 
potent Pim selective inhibitor (124a) (Ki = 11 nM) was enhanced by modification of the 
cyclohexyl ring. A 4-hydroxycyclohexylamino analog (124b) (Figure 8A) with an improved 
aqueous solubility is reported to inhibit Pim-1 below the limit of the detection assay (Ki < 5 
nM) and to show a high level of selectivity when screened against a panel of 21 kinases.241 
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Figure 8.  A) Heteroaromatic Pim inhibitors with in vitro and in vivo activity. B) The crystal 
  structure of triazolo[4,3-b]pyridazine (X) bound to Pim-1. Key interactions with 
  Glu121 and Lys67 are highlighted in green.240 
3,5-Disubstituted indoles 
In 2011, Nishiguchi et al.242 described a potent pan-Pim inhibitor identified by high-
throughput screening with a novel heteroaromatic 1H-pyrazolo[3,4-b]pyridine scaffold 
(125a, X, Y = N) (Figure 9). Despite the fact that (125a) had attractive potency against all 
three Pim isoforms (IC50: Pim-1, Pim-2, Pim-3: 9 nM, 39 nM 12 nM, respectively) it 
showed  low  nanomolar  activity  against  several  other  kinases  as  well,  and  contained  a  
possible metabolically labile phenolic group. The X-ray crystal structure studies revealed 
that only one of the N–H of the 1H-pyrazolo[3,4-b]pyridine core makes a hydrogen bond to 
the hinge region, while the two other nitrogens do not. The nitrogen deletion on the 
heteroaromatic core yielded the corresponding 1H-pyrrolo[2,3-b]pyridine (125b)  and  1H-
indole (125c) keeping the substitutions at C3 and C6 (Figure 9).242 While the pyrrolo[2,3-
b]pyridine  core  (125b) lost potency against all three Pims (3–7-fold), the indole core 
compound (125c) was able to retain the potency against the target while being completely 
inactive (> 25 ?M) against the other three kinases tested. The replacement of phenolic motif 
at  C6  of  (125c) was, however, a highly challenging effort and drove the investigation 
towards developing alternative substitution patterns on the scaffold.  
Based on the X-ray structure, the C5 position of the azaindazole core points towards 
Lys67 and a favorable interaction could be attained with a hydrogen-bond acceptor 
substituent. Several X-ray crystal structures of inhibitors bound to Pim-1 effectively take 
advantage of this interaction. One of these compounds, such as 5-aminopyrimidine-
substituted benzo[c]isoxazole (126)  (Figure  9)  has  nanomolar  affinity  for  Pim-1  (Ki = 91 
nM).240 Substituents at the C5 position placed on the more kinase selective indole scaffold 
yielded a series of heteroaromatic compounds, of which 2-pyrazine and 3-pyridine (127) 
analogs were the most potent (Figure 9).  
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Fixure 9.  Development of a novel indole-based inhibitor against Pim kinases. 
 
Replacement of the C3-phenylpiperazine with the 2-fluoroaminopyridine ring and 
introduction of either rigid or flexible basic amino substitutions at C6 of the pyrazine ring 
yielded very potent inhibitors (Figure 9), reaching the limits of detection of the biochemical 
assay as found for methyl-analog (128a) (IC50 Pim-1: <2 nM, Pim-2: 56 nM, Pim-3: <2 
nM).242 When  R1 was replaced with ethyl in (128b) a two-fold improvement (Pim-2: 26 
nM) was observed. The Pim-2 potency suffered as the substituent grew larger as shown for 
isopropyl and tert-butyl groups (128c–128d). The phenyl moiety of (128e) was, however, 
well-tolerated, showing the highest affinity of all compouds against Pim-1, Pim-2, and Pim-
3 (<2 nM, 10 nM, <2 nM, respectively).  The tert-butyl analog (128c) was further profiled 
and found to display high selectivity over a panel of 30 other protein kinases (>10 ?M). 
Pyrrolocarbazoles  
Pyrrolo[2,3-a]carbazoles have been identified recently as a new scaffold for potent Pim 
kinase inhibitors.243,244 Compound (129a, DHPCC-9) (Figure 10A), substituted at the C3 
position by a formyl group, exhibited a potent and selective inhibition of all Pim kinases 
when tested toward a panel of 66 protein kinases, with a high activity against Pim-3 (IC50 = 
10 nM).243 Recently, (129a) was reported to slow down migration and invasion of cancer 
cells derived from either prostate cancer or squamocellular carcinoma patients, thus 
represents an attractive compound for drug development to inhibit the invasiveness of Pim-
overexpressing cancer cells.245  
 
Figure 10.  A) Pyrrolo[2,3-a]carbazoles (129a–e). IC50 values for Pim-1, 2 and 3 in brackets. 
  B) Interatomic distances (Å) between C7 and C8 positions of pyrrolocarbazole 
  (129a) and Pim-1 kinase hinge residues (PDB code 3JPV). The hydrogen bond 
  between the formyl group and the Lys67 side chain is indicated in red.244 
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When the phenyl ring was further substituted with a bromine atom at various positions, 
compound (129b)244 (Figure  10A)  bearing  a  Br  atom  at  C6,  was  reported  to  be  the  most  
potent inhibitor of Pim kinases in the series, with a 17-fold higher activity toward Pim-1 
compared to (129a). The best Pim-3 inhibitor was, however, the analog (129c), with a CF3 
substituent at C9 (IC50 = 6 nM).244 The diversely C6–C9 phenyl ring-substituted analogs 
(129a–e, Figure 10A) were evaluated for their in vitro antiproliferative potencies toward 
three cancer cell lines (PA1, PC3, and DU145) and a fibroblast primary culture, revealing 
IC50 values in the low micromolar range.243,244 The  crystal  structure  of  Pim-1  complexed  
with (129a) was determined, revealing a non-ATP mimetic binding mode with no hydrogen 
bonds formed with the kinase hinge region (Figure 10B).244 
Benzothienopyrimidin-4-ones 
Tao et al.,246 from the Abbott Laboratories, recently reported a series of 69 
benzothienopyrimidinones (130, Figure 11) as novel and potent Pim kinase inhibitors that 
do not only inhibit all three Pim kinases at subnanomolar concentrations but also exhibit 
excellent kinase selectivity. The reported inhibitors efficiently interrupted the 
phosphorylation of BAD in both leukemia and prostate adenocarsinoma cell lines (K562 
and LnCaP-Bad, respectively), indicating that their potent biological activities are 
mechanism-based. In the comprehensive search for a pan-Pim kinase inhibitor, the initial 
SAR study of the 2-position of the pyrimidone ring gave compound (130a, Figure 11), with 
a 3-hydroxyphenyl substituent pose high affinity for Pim-1, but only modest affinity for 
Pim-2 (Ki = 0.9 nM, 147 nM, respectively).  
 
 
Figure 11. Some members of the benzothienopyrimidin-4-one library with Ki values in table.  
The subsequent SAR study of the phenyl ring at C8 showed that the introduction of a 
simple halogen atom (130b,  R1 = Cl; 130c,  R1 = Br), or alkyl group (130d,  R1 = CF3) 
dramatically increased the affinity. The hydrophobic cyclopropylvinyl group in (130e) 
further increased the Pim-1 and Pim-2 inhibition to a single-digit nanomolar level. The 
same was observed in analogs with five- and six-member aromatic rings at C8 (130f–i).246 
Combination  of  the  (S)-3-hydroxypyrrolidinyl group at the 2-position with the p-phenolic 
group at 8-position resulted in the compound (130i, Figure 11), with most potent inhibition 
of all three Pim kinases and over 1000-fold higher affinity for Pim-1 and Pim-3 over 15 
other kinases.246 Another potent analog  (130f) is highly bioavailable, exhibiting 
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bioavailability of 76% with oral dosing. It has shown inhibition of the growth of K562 cells 
(EC50 = 1.7 ?M) and low nanomolar Ki values against Pim-1, Pim-2 and Pim-3 (2, 3, and 
0.5 nM, respectively). Further ADME profiling suggested a long half-life in human and 
mouse liver microsomes, in addition to good permeability, modest protein binding, and no 
considerable CYP inhibition below 20 ?M concentration.246 
Pyrazinyl cinnamic acids 
In 2009, the group of Morwick247 from Boehringer Ingelheim Pharmaceuticals reported a 
comprehensive study of pyrazinyl carboxylic acid inhibitors of Pim-2 kinase. A high-
throughput screen hit (131a, Figure 12) showed an unconventional binding mode to Pim-1, 
as revealed by X-ray crystallography. The X-ray data illustrated that the inhibitor binds to 
the highly negatively charged cleft between two lobes of Pim-1 and reveals the unusual lack 
of hinge binding. The carboxyl group of the inhibitor forms a salt bridge with a bound Mg2+ 
that in turn forms a salt bridge with Glu89 from the ?C helix.247 Additionally, the carboxyl 
group of the inhibitor forms a hydrogen bond directly with Lys67. The basic nitrogen of the 
homopiperazine (1,4-diazepane) group is located in a region aligned with three acidic 
residues (Asp131, Asp128 and Glu171) and forms water-mediated hydrogen bonds with 
two of them. (131a) is highly selective within the kinase family, and shows similar potency 
for both Pim-1 and Pim-2 (IC50 57 nM and 40 nM, respectively). The compound has a good 
solubility and acceptable cell permeability with a good half-life in human liver microsomes, 
and no CYP inhibition below 30 ?M.247 A complete removal of the cinnamic acid portion 
generated an inactive compound, suggesting that the cinnamic acid fragment contributes 
more significantly to the potency than the homopiperazine. The bioisosteric tetrazole (131b) 
can apparently engage the network of interactions observed for the carboxylic acid to some 
extent. It has a potency within 4-fold that of a hit compound (131a). 
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Figure 12.  Disubstituted pyrazine cinnamic acids by Boehringer Ingelheim Pharmaceuticals. 
 
Removal of the methyl substituent from the distal amine of (131a) gave secondary amine 
(131c) with a low nanomolar affinity for Pim-2 (IC50 = 10 nM).247 Among cyclic six-
membered analogs (132a–d) and acyclic diamines (132e–f) (Figure 12), the compound 
(132c)  with  a trans-cyclohexane-1,4-diamino substituent showed the most potent Pim-2 
inhibition. The removal of the basic diamino fragment resulted in compound (132g), which 
is significantly less potent against Pim-2. The same authors responded to claims concerning 
the ?,?-conjugated cinnamic acid moiety, which may potentially act as a Michael acceptor, 
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enhancing the affinity of (131a)  by  covalent  modification  of  the  protein.  The  reversibile  
binding mode of (131a) for Pim-1 was evaluated by a time-dependent assay with varying 
concentrations of ATP, where the results suggested a reversible binding mode. The X-ray 
structure of (131a) confirmed this observation, as an examination of the area near the ?-
carbon to the acid revealed no nucleophilic residues within bonding distance to the 
protein.247 
Benzofuran-2-carboxylic acids 
In 2011, Xiang et al. from Genzyme Corp. identified benzofuran-2-carboxylic acids (Figure 
13) as Pim-1 inhibitors by fragment-based screening.248 The X-ray crystal structure of 
compound (133) bound to Pim-1 shows the salt bridge interaction of 2-carboxyl group with 
Lys67 and the hydrophobic interactions of the C5 Br-substituent surrounded by the 
hydrophobic pocket of the Pim-1 hinge region. The authors replaced the 5-bromo 
substituent of compound (133) with an extended linker fragment containing a basic 
heterocyclic moiety to capture additional interactions with acidic amino acid residues 
(Asp128 and Glu171) in the ribose binding region, while maintaining the benzofuran-2-
carboxylic acid framework unchanged. An appropriate distance between the terminal amino 
group and the benzofuran core appeared to be critical in achieving high potency. The most 
potent of this series, meta-substitued pyrazine compound (134), with a primary aliphatic 
amino  substituent,  had  IC50 values of 53 nM for Pim-1 and 21 nM for Pim-2. The 
compound (134) shares obvious structural similarities with pyrazinyl cinnamic acids (131–
132), reported the Morwick group247 (vide supra). 
 C5 bromo analogs carrying a basic moiety at the C7 position of the benzofuran framework 
were also studied (Figure 13). The nature of the linker does not seem to be very important; 
however, the basicity of the nitrogen center of the terminal amine is a significant factor 
impacting the potency, as evidenced by comparing the Pim-1 and Pim-2 inhibition of 
compounds with terminal piperidine, to compounds with terminal pyridine. Replacing the 
amino group with a hydroxy group diminishes the activity. The X-ray crystal structure 
analysis  of  analog  (135a)  showed  that  the  concise  and  rigid  cis-diaminocyclohexyl ring 
possessed an ideal shape to position the terminal amino residue in the right distance and 
orientation, allowing for strong interactions with Asp128 and Glu171.  
 
 
Fixure 13. Genzyme’s benzofurancarboxylic acids as Pim-1 and Pim-2 inhibitors. 
 
The compound (135a) is capable of strong binding and inhibition of both Pim-1 and Pim-2 
as demonstrated by IC50 values  of  1.0  nM  and  4.0  nM,  respectively.  Terminal  piperidine  
analog (135b) (IC50 = 20 nM for Pim-1) was tested using an Ambit 442 kinase panel (at 100 
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nM concentration). Under these conditions, in addition to Pim-1, Pim-2, and Pim-3, only 
three non-Pim kinases were inhibited (>50% of the binding), which indicates the good 
selective nature of this structural class against the Pim kinase family. Both compounds 
(135a, 135b) were inactive against a set of five CYP isozymes, demonstrated adequate 
aqueous solubility, and were moderately stable in rat and human liver microsome metabolic 
stability assays. 
 
(5-Arylfuran-2-yl)methylene indolin-2-ones  
 
In 2011, Cylene Pharmaceuticals reported a high-throughput screening (HTS) hit compound 
(136) (Figure 14) containing an oxindole group as an inhibitor of Pim-1 kinase (IC50 = 386 
nM).249 The inhibitor shows some structural features similar to pyrazinyl cinnamic acids 
(131–132)  (vide supra).  A  SAR  study  resulted  in  a  series  of  19  analogs  (137), including 
variation of the carboxylic acid moiety with aliphatic basic amines (R1), incorporation of 
nitrogen atoms to the m-substituted phenyl ring (X1,  X2) and various halogen substituents 
(R2), and substitution around the indole ring (R4)  and  the  (E)-alkene (R3).  This  led  to  a  
discovery of (138) (Figure 14), a novel pan-Pim kinase inhibitor with high efficiency (IC50 
Pim-1: 5 nM, Pim-2: 25 nM, Pim-3: 16 nM) and moderate pharmacokinetic profile. The 
authors showed that compound (138) was Pim-selective, since only Pim-1, Pim-2, Pim-3, 
and Flt-3, of the 107 screened kinases were, inhibited by more than 80% (at 0.5 ?M 
concentration).249 The  antiproliferative  activity  of  (138)  was  examined  against  a  panel  of  
cell lines derived from human solid tumors and hematological malignancies, where it 
demonstrated robust antiproliferative potencies against all cell lines tested. Cell lines 
derived from acute leukemias were the most sensitive. In addition, in combination with 
chemotherapeutics, compound (138) exhibited synergistic antiproliferative activity and 
displayed significant in vivo efficacy in acute myeloid leukemia (MV-4-11) and prostate 
adenocarcinoma (PC3) human xenograft models representing the diseases, where Pim 
kinases have been shown to play an important role. 
 
 
Fixure 14. Development of pan-Pim kinase inhibitor by Cylene Pharmaceuticals. 
 
Miscellaneous Pim inhibitors 
 
Among the naturally occurring plant-derived flavonoids, quercetagetin (139a) shows 
moderate affinity for Pim-1 (IC50 = 340 nM).250 However, quercetagetin has been identified 
as a highly selective inhibitor of Pim-1 over Pim-2 and other serine-threonine kinases (e.g. 
PKC and PKA), with both in vitro assays and in cell cultures. The X-ray crystal structure of 
(139a) bound to the ATP-binding site of Pim-1 shows that the compound orients the B ring 
inside the pocket.249 The hydroxy group of the C ring in (139a) makes a canonical hydrogen 
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bond with backbone carbonyl oxygen of the hinge residue Glu121. Another flavonol 
quercetin (139b), a non-specific inhibitor of protein kinases and other enzymes, is reported 
to have nanomolar inhibition against Pim-1 (IC50 = 43 nM).228 A  much  weaker  affinitity  
was reported (IC50 = 1.1 ?M) by Holder et al. 250 for the same compound (139b), however. 
The HTS hit (140a), containing an isoxazoloquinoline-3,4-dione core was reported to be 
a potent inhibitor for Pim-1 and Pim-2 kinases (Ki = 22 nM and 174 nM, respectively).251 
Synthesis of a small library, and installation of a hydroxy group on the phenyl ring of the 
core resulted in the most potent inhibitor (140b), with a potential to form a key hydrogen 
bond interaction with the hinge region and Ki values of 2.5 and 43.5 nM against Pim-1 and 
Pim-2, respectively, and displayed an activity profile with a high degree of selectivity 
among a panel of 22 kinases.251 
Aryl-substituted thiazolidine-2,4-dione (141a) was identified by screening to be a Pim-1 
inhibitor.252 Computational lead optimization led to the synthesis of a library of substituted 
thiazolidine-2,4-diones, where the most potent compound (141b) showed an IC50 of 13 nM 
for Pim-1 and compound (141c) showed an IC50 value of 20 nM for Pim-2. Despite high 
potency against Pim-1 and 2, the screened compounds were unable to inhibit Pim-3 
efficiently. 
 
 
 
Series of substituted pyridones were reported as potent inhibitors of Pim-1 kinase.253 The 
diaryl-substituted pyridine (142) inhibits Pim-1 at 50 nM (IC50) in vitro. The X-ray structure 
of (142) with Pim-1 showed a large hydrogen bond network between the carbonyl group on 
the pyridine ring, Lys67, Phe187, and two water molecules. An additional weak hydrogen 
bond between the aromatic hydrogen on the phenol ring and the main carbonyl chain of 
Glu121 contributes to the stabilization of the molecules.253    
   Finally, Genzyme Corp. recently published a highly potent compound derived from a 
fragment-based drug design program. In this program, the analysis of nuances of fragment 
binding of known Pim-inhibitors led to the synthesis of a compound (143) with an 
impressive IC50 of 467 pM.254 
 
Summary of the natural and synthetic compounds targeting Pim kinases 
 
Only few natural products have been identified as Pim kinase inhibitors, including 
staurosporine, bis(indolyl)maleimides, and flavonoids. While staurosoporine (93), BIM-1 
(119), and quercetin (139b) inhibit Pim kinases potently, they lack selectivity by inhibiting 
 
 
45 
 
a variety of other protein kinases, thus leaving the therapeutic usefulness of such 
compounds unclear. Synthetic compounds with selective Pim inhibition have emerged, 
however, especially within last 5 years (vide infra). 
Staurosporine-mimicking ruthenium complexes such as (121a–b) have shown to be 
highly effective Pim kinase inhibitors with excellent kinase selectivity. These complexes 
seem to behave like “regular” organic compounds without displaying metal-related 
cytotoxicities. The importance of these compounds was further demonstrated in the 
elucidation of the crystal structure of Pim-2 kinase with an organoruthenium complex (rac-
120a). 
In a class of imidazo and triazolopyridazines, several potent and selective Pim-1 
inhibitors have been developed. For example, compound (122a) has in vitro antileukemic 
potential shown in various cell line models and in AML patients’ samples. Another 
heterocyclic compound (129a, DHPCC-9) with a pyrrolo[2,3-a]carbazole structure is 
reported to be a potent inhibitor of Pim-3 (IC50 = 10 nM) and has recently shown to slow 
down migration and invasion of cancer cells, thus represents an attractive compound for 
drug development to inhibit invasiveness of Pim-overexpressing cancer cells.  
Within the last 2–3 years, the pharmaceutical industry has shown an emerging interest in 
Pim kinases, and several pharmaceutical companies have launched Pim inhibitors with 
novel scaffolds combined with high potency and kinase selectivity. In 2009, SuperGen 
(now Astex Pharmaceuticals) developed imidazo[1,2-b]pyridazine (122b, SGI–1776) with a 
reported low nanomolar affinity for Pim-1 (IC50 = 7.0 nM). SGI–1776 advanced to phase I 
clinical trials, and therefore became the first clinical-stage investigational drug specifically 
targeting Pim kinases.  
In the same year, Abbott Laboratories discovered benzothienopyrimidinones (130) as a 
novel class of Pim inhibitors possessing low nanomolar Ki values against all three Pim 
kinases while maintaining kinase selectivity. Multiple compounds exhibited potent 
antiproliferative activity in cell cultures with submicromolar EC50 values and 
pharmacokinetic studies suggested that these Pim inhibitors are highly bioavailable.   
In 2009, Boehringer Ingelheim Pharmaceuticals reported a comprehensive study of 
pyrazinyl cinnamic acids (131–132) as efficient inhibitors of Pim-2 kinase. One of the 
studied analogs (131c), with a low nanomolar (IC50 =  10  nM) affinity  for  Pim-2,  showed 
good aqueous solubility, acceptable permeability, and a good half-life in human liver 
microsomes. 
In 2011, Cylene Pharmaceuticals developed indolin-based novel pan-Pim kinase 
inhibitors. The compound (138) displays high potency in mechanistic and antiproliferative 
cellular assays and shows synergistic antiproliferative activity in combination with 
chemotherapeutics. In addition, (138) showed significant in vivo efficacy in two xenograft 
models representing the diseases, where Pim kinases have been shown to play an important 
role. 
In 2011, Genzyme Corp. identified benzofuran-2-carboxylic acids as selective Pim-1 
inhibitors. The most potent compound (135a) is able to inhibit Pim-1 and Pim-2 with 
single-digit IC50 values (1.0 nM and 4.0 nM, respectively). In 2012, the same company 
published very potent compound (143) showed impressive IC50 of 467 pM for Pim-1.  
Although no PIM kinase inhibitor has successfully reached in the clinical use yet, the 
intense effort of many groups to develop potent and selective inhibitors of PIM kinases will 
obviously lead to clinically useful drugs. 
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3 Aims of the study 
The objective of this study was to synthesize various six-membered compounds, including 
both carbo and heterocyclic ring systems, with possible interesting biological properties. 
Both solid- and solution-phase methods were studied. 
 
The more specific aims of the research were 
 
? to study and develop a practical synthetic method the for aza Diels-Alder reaction 
between polymer-bound diene and N=N azadienophiles on solid-phase including 
synthesis of hexahydrocinnoline derivatives (I); 
? to synthesize 4-aminoguaiazulene and utilize it in a preparation of heterocyclic 
benzo[cd]azulenes (II); 
? to  design  and  synthesize  a  model  compound targeted  to  the  C1 domain  of  PKC 
and evaluate its biological activity. In the synthetic study, the cascade of two 
Diels-Alder  cycloadditions  was  used  as  the  key  reaction  in  a  construction  of  the  
tricyclic framework of the model compound (III); 
? to synthesize novel benzo[cd]azulene derivatives and to study their capability of 
inhibiting Pim kinases (IV). 
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4 Experimental 
A detailed presentation of the materials, synthetic, and analytical methods can be found in 
the original publication III, and in the supporting information for original publications I, II, 
and IV. The supporting information for original publications I, II, and IV is not included in 
this thesis. This material is available from the author or via the Internet at 
http://pubs.acs.org for original publication I (56 pages), and at 
http://www.sciencedirect.com/ for original publication II (9 pages). The experimental 
procedures and analytical data for the unpublished compounds are presented in this chapter. 
 
1-Methyl-4-(prop-2-yn-1-yloxy)-3-(trifluoromethyl)-8H-benzo[cd] 
azulen -8-one (144). 
Tropone (48c) (0.10 g, 0.36 mmol) was dissolved in acetone (10 mL), then powdered 
potassium carbonate (0.10 g, 0.81 mmol, 2.3 equiv) and propargyl bromide (80 wt % in 
toluene, 90 ?L, 0.81 mmol, 2.3 equiv) were added to the reaction mixture. The resulting 
mixture was stirred at ambient temperature for 2 days. TLC analysis of the reaction mixture 
showed the formation of a yellow product and the disappearance of an orange starting 
material. EtOAc (10 mL) and water (5 mL) were added, and phases were separated. The 
aqueous phase was extracted with EtOAc (2 ? 10 mL) and the combined organic phases 
were dried over anhydrous Na2SO4, filtered, and evaporated to dryness. The obtained crude 
product was purified by column chromatography on silica gel (eluent: EtOAc/n?hexane 
1:1) to give (144) (69 mg, 61%) as a yellow solid. M. p. 161–163 °C; 1H NMR (300 MHz, 
CDCl3): ? 7.28 (H, d, J = 12.6 Hz), 7.04 (1H, m), 7.02 (1H, d, J = 2.4 Hz), 6.98 (1H, s), 
6.89 (1H, dd, J = 2.4 Hz, 12.6 Hz), 4.88 (2H, d, J = 2.1 Hz ), 2.60 (1H, t, J = 2.1 Hz) 2.24 
(3H, d, J = 1.5 Hz) ppm; 13C NMR (75 MHz, CDCl3): ? 188.1, 157.1, 148.9, 144.6, 143.5, 
138.6, 137.6, 134.4, 131.2, 131.1 (q, J = 4.8 Hz), 127.4, 123.7 (q, J = 273.0 Hz), 115.5, (q, J 
= 32.0 Hz), 112.2, 77.3, 77.1, 57.2, 13.0 ppm; Anal. calc. for C18H11F3O2 (316.07): C, 
68.36; H, 3.51. Found: C, 68.09; H, 3.29; LC–MS: [M+H]+ m/z 317. 
 
4-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methoxy]-1-methyl-3-(trifluoro- 
methyl)-8H benzo[cd]azulen-8-one (145). 
Alkyne (144) (94 mg, 0.30 mmol) was dissolved in a mixture of DMF?H2O (4:1, 5 mL) and 
benzyl bromide (43 µL, 0.36 mmol, 1.15 equiv), sodium azide (65 mg, 0.36 mmol, 1.15 
equiv), then an aqueous 1.0 M solution of CuSO4 (0.07 mmol, 70 µL, 0.2 equiv) and 
sodium ascorbate (29 mg, 0.14 mmol, 0.5 equiv) were added. The reaction mixture was 
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irradiated in a microwave reactor at 120 °C for 35 min. The resulting precipitate was 
washed with dilute aqueous ammonia solution (3 ? 10 mL) and after drying, the obtained 
crude product was purified by column chromatography on silica gel (eluent: 
EtOAc/n?hexane 3:1) to give (145) (42 mg, 31%) as a yellow solid. M. p. 251 °C 
(decomp.); 1H NMR (300 MHz,) DMSO-d6): ? 8.30 (1H, s), 7.57 (1H, s), 7.55 (H, d, J = 
12.9 Hz), 7.40?7.28 (4H, m), 7.05 (1H, s), 6.98 (1H, dd, J = 2.4 Hz), 6.86 (1H, dd, J = 2.4 
Hz, 12.9 Hz), 5.64 (2H, s), 5.40 (2H, s) 2.23 (3H, s) ppm; 13C NMR (75 MHz, DMSO-d6): ? 
186.9, 157.2, 147.7, 145.0, 142.3, 142.0, 138.5, 137.2, 136.0, 134.6, 130.9, 129.9, 128.7, 
128.7, 128.1, 127.8, 127.8, 125.6, 124.8, 123.6 (q, J = 273.0 Hz), 113.0 (q, J = 31.0 Hz), 
113.0, 62.9, 52.8, 12.4 ppm; Anal. calc. for C25H18F3N3O2 (449.14): C, 66.81; H, 4.04; N, 
9.35. Found: C, 66.54; H, 3.89; N, 9.16; GC–MS: [M]+ m/z 449. 
 
Methyl 2-[[1-methyl-8-oxo-3-(trifluoromethyl)-8H-benzo[cd]azulen-4-
yl]oxy]acetate (146). 
Tropone (48c) (0.10 g, 0.36 mmol) was dissolved in acetone (8 mL), then powdered 
potassium carbonate (0.10 g, 0.36 mmol) and methyl bromoacetate (102 ?L, 1.08 mmol, 3.0 
equiv) were added to the reaction mixture. The resulting mixture was stirred at ambient 
temperature  for  3  days.  TLC  analysis  of  the  reaction  mixture  showed  the  formation  of  a  
yellow product and the disappearance of an orange starting material. EtOAc (10 mL) and 
water (5 mL) were added and phases were separated. The aqueous phase was extracted with 
EtOAc (2 ? 10 mL) and the combined organic phases were dried over anhydrous Na2SO4, 
filtered, and evaporated to dryness. The obtained crude product was purified by column 
chromatography on silica gel (eluent: EtOAc/cyclohexane 1:1) to give (146) (60 mg, 48%) 
as bright yellow needles. M. p. 177–179 °C; 1H NMR (300 MHz, CDCl3): ? 7.22 (H, d, J = 
12.6 Hz), 7.05 (1H, m), 7.02 (1H, d, J = 2.4 Hz), 6.88 (1H, dd, J = 2.4 Hz, 12.6 Hz), 6.68 
(1H, s), 4.81 (2H, s), 3.83 (3H, s), 2.25 (3H, s) ppm; 13C NMR (75 MHz, CDCl3): ? 188.0, 
168.2, 157.5, 148.8, 144.8, 143.7, 138.3, 137.7, 134.4, 131.3, 131.1 (q, J = 5.0 Hz), 127.6, 
123.4 (q, J = 273.0 Hz), 115.4, (q, J = 32.0 Hz), 114.4, 66.2, 52.7, 12.9 ppm; Anal. calc. for 
C18H13F3O4 (350.08): C, 61.72; H, 3.74. Found: C, 61.46; H, 3.51; LC–MS: [M+H]+ m/z 
351. 
 
2-[[1-Methyl-8-oxo-3-(trifluoromethyl)-8H-benzo[cd]azulen-4-yl]oxy]- 
acetic acid (147). 
To a solution of methyl ester (146) (97 mg, 0.28 mmol) in THF?methanol?acetone?water 
(2:2:2:1) (15 mL) at room temperature, lithium hydroxide hydrate (18 mg, 0.42 mmol, 1.5 
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equiv) was added, and the resulting mixture was stirred at room temperature until TLC 
analysis indicated complete consumption of the starting material (90 min). EtOAc (20 mL) 
and brine (10 mL) were added and the resulting mixture was acidified with aqueous 1 M 
HCl (5 mL). Layers were separated and the aqueous phase was extracted with EtOAc (2 × 
10 mL). The organic phase was dried over anhydrous Na2SO4, filtered, and the solvents 
were removed on a rotary evaporator to yield (147) as orange crystals (90 mg, 96%) without 
a need for further purification. M. p. 270–271 °C (decomp.); 1H NMR (300 MHz, DMSO-
d6): ? 13.19 (1H, br s), 7.55 (H, d, J = 12.6 Hz), 7.32 (1H, s), 7.17?7.07 (1H, m), 7.00 (1H, 
d, J = 2.4 Hz), 6.84 (1H, dd, J = 2.4 Hz, 12.6 Hz), 4.95 (2H, s), 2.25 (3H, d, J = 1.2 Hz ) 
ppm; 13C  NMR  (75  MHz,  DMSO-d6): ? 186.9, 169.0, 157.1, 147.5, 144.9, 142.3, 138.3, 
137.1, 134.5, 130.8, 129.9 (q, J = 4.6 Hz), 125.6, 123.6 (q, J = 273.0 Hz), 113.0, (q, J = 
31.0 Hz), 112.3, 65.4, 12.3 ppm; Anal. calc. for C17H11F3O4 (336.06): C, 60.72; H, 3.30. 
Found: C, 60.90; H, 3.29; LC–MS: [M+H]+ m/z 337. 
 
CF3
OH
H
S
(148) (±)-2-(Benzylthio)-8-isopropyl-1-methyl-4-(trifluoromethyl)-
2H-benzo[cd]azulen-3-ol (148). 
Benzo[cd]azule-3-one (36c) (100 mg, 0.33 mmol) was dissolved in anhydrous ethanol (4 
mL) and benzylthiol (85 µL, 0.66 mmol, 2 equiv) was added. The reaction mixture was 
stirred at room temperature under argon atmosphere until TLC analysis indicated the 
complete consumption of the green starting material (1.5 h) and formation of an orange 
product. The reaction mixture was evaporated to constant weight on a rotary evaporator and 
the obtained crude product was purified by column chromatography on silica gel (eluent: 
EtOAc/n?hexane 1:8) to give (148) as an orange solid (118 mg, 81%). M. p. 114–116 °C 
(dec.); 1H NMR (300 MHz, CDCl3): ? 7.31 (1H, m), 7.23–7.12 (3H, m), 7.08 (1H, d, J = 1.8 
Hz), 7.06 (1H, m), 7.01 (1H, s), 5.99 (1H, d, J = 12.6 Hz), 5.90 (1H, s), 5.50 (1H, dd, J = 
1.8 Hz, 12.6 Hz), 4.30 (1H, s), 3.32 (1H, d, J = 13.2 Hz), 3.22 (1H, d, J = 13.2 Hz),  2.28 
(1H, septet, J = 6.9 Hz), 1.81 (3H, d, J = 0.9 Hz), 1.09 (6H, d, J = 6.9 Hz) ppm; 13C NMR 
(75 MHz, CD2Cl2): ? 152.2, 149.7, 144.8, 139.3, 137.8, 134.5, 132.5, 130.5, 129.5, 129.5, 
128.9, 128.9, 128.0, 127.7, 127.7, 125.8, 124.3 (q, J = 271 Hz), 122.3, 115.6 (q, J = 31 Hz), 
53.1, 38.7, 32.7, 22.2, 22.1, 11.4 ppm; Anal. calc. for C25H23F3OS (428.14): C, 70.07; H, 
5.41. Found: C, 69.79; H, 5.30. 
 
CF3
OH
OMe
O
PPh3
H
(149) (±)-Methyl 2-(3-hydroxy-8-isopropyl-1-methyl-4-(trifluoro- 
methyl)-2H-benzo[cd]azulen-2-yl)-2-(triphenylphosphoranylidene)acetate (149). 
To a solution of methyl (triphenylphosphoranylidene)acetate (110 mg, 0.33 mmol, 1.5 
equiv) in anhydrous THF (5 mL) a solution of benzo[cd]azulen-3-one (36c) (75 mg, 0.25 
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mmol, 1.0 equiv) in THF (3 mL) was added at ?15 °C under argon atmosphere. After 15 
min, the cold bath was removed, and the reaction mixture was allowed to warm up to room 
temperature. TLC analysis indicated the complete consumption of green starting material 
and formation of a bright yellow product (90 min). EtOAc (20 mL) and water (10 mL) were 
added, and phases were separated. The aqueous phase was extracted with EtOAc (2 ? 10 
mL) and the combined organic phases were dried over anhydrous Na2SO4, filtered, and 
evaporated to dryness. The crude product was purified by column chromatography on silica 
gel  (eluent:  EtOAc/Cyclohexane  1:5)  to  give  (149) as a light-orange powder (112 mg, 
70%). Some material was lost during the purification since the product is unstable in acidic 
media. M. p. 142–144 °C (dec.); 1H NMR (300 MHz, C6D6): ? 11.16 (1H, br s), 7.54–7.40 
(6H, m), 7.10–6.94 (10H, m), 5.62 (1H, d, J = 12.3 Hz), 5.17 (1H, s), 5.09 (1H, dd, J = 1.8 
Hz, 12.3 Hz), 4.88 (1H, d, J = 28.2 Hz), 3.02 (3H, s), 1.93 (1H, septet, J = 6.9 Hz), 1.38 
(3H, d, J = 1.2Hz), 0.93 (6H, d, J = 6.9 Hz) ppm; 13C NMR (75 MHz, acetone–d6): ? 175.5 
(d, J = 12 Hz), 153.6, 150.8, 142.0, 138.5, 137.3, 136.4, 134.4 (d, J = 10 Hz) × 3, 133.1 (d, 
J = 12 Hz) × 6, 133.2, 129.3 (d, J = 12 Hz) × 9, 128.2 (q, J = 5 Hz), 126.4, 125.7 (q, J = 270 
Hz), 124.7, 122.7, 114.3 (q, J = 30 Hz), 51.5 (d, J = 12 Hz), 50.4, 38.4, 38.2 (d, J = 118 
Hz), 22.1, 21.8, 13.0 ppm; Anal. calc. for C39H34F3O3P (638.22): C, 73.34; H, 5.37. Found: 
C, 73.49; H, 5.11; HRMS-ESI m/z: calc. for C39H34F3O3P [M+H]+: 639.2276, found 
639.2136. 
 
2-Amino-8-isopropyl-1-methyl-4-(trifluoromethyl)-3H-benzo[cd]- 
azulen -3-one (150). 
Benzo[cd]azulen-3-one (36c) (100 mg, 0.33 mmol) was dissolved in methanol (8 mL) and 
hydroxylamine hydrochloride (184 mg, 2.65 mmol, 8 equiv) and ammonium acetate (205 
mg, 2.65 mmol, 8 equiv) were added. The reaction mixture was stirred for 3 days under 
argon atmosphere. TLC analysis indicated a formation of a polar product. EtOAc (20 mL) 
and saturated solution of sodium hydrogencarbonate (10 mL) were added and phases were 
separated. The aqueous phase was extracted with EtOAc (2 ? 10 mL), and the combined 
organic phases were dried over anhydrous Na2SO4, filtered and evaporated to dryness. The 
crude product was purified by column chromatography on silica gel (eluent: 
EtOAc/n?hexane 1:2) to give (150) as a dark, brownish-green solid (40 mg, 38%). M. p. 
237 °C; 1H NMR (300 MHz, DMSO-d6): ? 9.03 (1H, br s), 8.77 (1H, br, s), 8.13 (1H, s), 
7.63 (1H, s), 7.61 (1H, dd, J = 1.5 Hz, 11.7 Hz), 7.16 (1H, dd, J = 1.5 Hz, 11.7 Hz), 3.10 
(1H, septet, J = 6.9 Hz), 2.25 (3H, s), 1.30 (6H, d, J = 6.9 Hz) ppm; 13C NMR (75 MHz, 
CDCl3): ? 174.9, 163.9, 155.1, 146.5, 141.0, 137.3, 134.4, 130.9 (q, J = 28 Hz), 128.5, 
125.7, 123.4, 123.3 (q, J = 272 Hz), 112.3, 109.1, 40.3, 24.4, 24.4, 7.8 ppm; Anal. calc. for 
C18H16F3NO (319.12): C, 67.70; H, 5.05; N, 4.39. Found: C, 66.37; H, 4.88; N, 3.98; 
HRMS-ESI m/z: calc. for C18H16F3NO [M+H]+: 320.1262, found 320.1262. 
 
 
 
51 
 
5 Results and discussion  
The overall findings of this thesis work are described in this chapter, including the synthesis 
of six-membered nitrogen-containing heterocyclic cinnoline derivatives by Diels-Alder 
reaction on solid-phase (Chapter 5.1), and the synthesis of a model compound targeted to 
the C1 domain of PKC by Diels-Alder methodology (Chapter 5.2). Chapter 5.3 focuses on 
the synthesis of new guaiazulene derivatives; synthesis of 4-aminoguaiazulene and its ?-
lactam derivatives (5.3.1) and synthesis of tricyclic benzo[cd]azulene derivatives as 
selective and potent Pim kinase inhibitors (Chapter 5.3.2). 
5.1 Synthesis of hexahydrocinnolines by aza Diels-Alder reaction 
Cinnoline (151) (1,2-diazanaphthalene) is an heteroaromatic compound and isosteric to 
either quinoline or isoquinoline. Therefore, many synthesized cinnoline compounds are 
designed as analogs of the previously obtained quinoline or isoquinoline derivatives.255 
Cinnoline itself shows antibacterial activity against Escherichia coli.255 While cinnoline 
derivatives have not been found in nature, the cinnoline moiety, and its various structural 
modifications, can be found in several pharmaceutically interesting compounds (Figure 15). 
Cintazone (152), for example, is a nonsteroidal anti-inflammatory agent, and cinoxacin 
(153) is a synthetic antimicrobial agent, both related to oxolinic and nalidixic acids and used 
in urinary tract infections. Certain cinnoline-related compounds are useful as antianxiety 
and antihypertensive agents. The Porco group has demonstrated the usefulness of the 
epoxyquinol scaffold in the synthesis of a structurally diverse chemical library,256 
structurally resembling the hexahydro-1,2,4-triazolocinnoline-3,5-diones synthesized in this 
study. Some members of the epoxyquinol library, such as compound (154) (Figure 15), 
specifically inhibited an induction of human heatshock protein (HSP 72) with IC50 value of 
1.5 ?M.256 From a 168-member oxime library, the extended urazole compound (155) 
(Figure 15) inhibited the growth of human small-cell lung carcinoma cell line (A549) with 
an IC50 value of 6.2 ?M.257 
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Figure 15.  Cinnoline and some biologically active cinnoline derivatives. 
 
As part of these studies on polymer-supported pericyclic reactions for preparing 
biologically interesting compounds, a practical synthetic method for the preparation of  
hexahydrocinnolines was developed. The synthesis of polymer-bound diene (156) (Scheme 
16) commences with the facile Grignard reaction of readily available 3-ethoxycyclohex-2-
enone (157) and vinylmagnesium bromide. This was followed by a reduction of the 
corresponding ketone with LiAlH4 in diethyl ether resulting in allylic alcohol (158) (75% 
over two steps). The hydroxy group of (158) was used as an anchor for coupling with the 
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polymeric support. After the deprotonation of the secondary alcohol (158) with sodium 
hydride, the resulting anion was linked with the commercially available bromo-Wang resin 
in the presence of tetra-n-butylammonium iodide and a catalytic amount of 15-crown-5 in 
THF which secured effective loading (Scheme 16). The residual bromide left on the resin 
(158) was determined by the volumetric Volhard method, with no residual bromide found. 
As mentioned in Chapter 2, TADs (1,2,4-triazole-3,5-diones) (159)  are  known  to  be  
excellent hetero dienophiles in the Diels-Alder reaction, since the lower LUMO energy of 
the N=N bond, in contrast to the corresponding C=C bond, in alkenes makes the reactions 
proceed more rapidly and often at ambient temperatures. 
The commercial availability of the urazoles was restricted during this study. However, 
the preparation of urazoles by condensing N-alkyl or N-aryl isocyanates and ethyl hydrazide 
carboxylate (160), followed by cyclization of intermediate (161) in a basic medium 
(KOH/H2O) turned out to be relatively straightforward (Scheme 16). Purification by 
recrystallization gave conveniently N-substituted urazoles (162), which can be stored as 
bench-stable azadienophilic precursors. Several oxidizing agents, including fuming nitric 
acid, lead peroxide, manganese dioxide, lead(IV) acetate, tert-butyl hypochlorite, and 
dinitrogen tetroxide, have been reported for the generation of N-substituted TADs (159).258 
However, all of these reagents, except dinitrogen tetroxide, form byproducts that are 
difficult to remove or are too reactive toward sensitive azo compounds. Hypervalent iodine 
oxidation with iodobenzene diacetate (IBD) was reported to be a mild and non-acidic way 
for  formation  of  (161).258 Intensive  and  rapid color change of the urazoles (162) (from 
colorless to dark red/violet) during IBD oxidation in situ indicates the formation of highly 
reactive dienophile species (159).  
 
 
Scheme 16.  Preparation of diene and dienophiles: synthesis of polymer-bound 3-vinyl-2-
  cyclohexen-1-ol and 1,2,4-triazole-3,5-diones. 
 
Commercially available N-phenyl-1,2,4-triazole-3,5-dione was found to participate 
effectively in the hetero Diels-Alder reaction with polymer-bound diene (156) at a 
temperature as low as -78 °C. The [4+2]-cycloaddition reaction was monitored by FT–IR 
spectroscopy, where the appearance of a strong characteristic carbonyl band at 1710 cm-1 in 
(163) (Scheme 17) revealed formation of the cycloadduct. The use of a higher reaction 
temperature (-10 °C vs -78 °C) did not show any difference in the stereoselectivity of the 
Diels-Alder reaction. In a similar fashion, the in situ generated N-aryl and N-alkyl TADs 
(159) participated in the aza Diels-Alder reaction, and the formed hexahydrocinnoline 
derivatives were cleaved from the resin in a traceless manner. Trifluoroacetic acid-mediated 
cleavage of the benzylic ether bond produced tricyclic cinnoline derivatives (164) as 
secondary alcohols. N-Aryl TADs gave slightly better yields (30–53%) compared to the N-
alkyl TADs generated in situ from the corresponding N-alkyl urazoles (26–35%). The 
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stereochemistry of single diastereomeric cycloadducts (164) was determined by 1H NMR 
studies, which showed that allylic proton Hb resonates  as  a  doublet  (3JHa-Hb = 8–10 Hz). 
This, together with a broad ddd (doublet of doublet of doublets) of homoallylic methine 
proton Ha indicates that protons Ha and  Hb are trans to  each  other  (Scheme  17),  as  was  
reported previously for the corresponding solution-phase reaction product (164, R = Ph).259  
 
 
Scheme 17.  Aza Diels-Alder on solid-phase: synthesis of cinnoline derivatives (164–165). 
  Isolated yields of cinnolines (164) after three reaction steps in brackets. 
 
The scope of the method was extended by using other types of carbonylazo compounds as 
cyclic azadienophiles. Indazolinone, maleic hydrazide, phthalhydrazide, and pyrazolidine-
3,5-dione were oxidized by IBD or lead (IV) acetate to the corresponding aza compounds 
and allowed to react with polymer-supported diene (156). The polymer-bound heterocycles 
were  released  from  the  resin,  as  their  corresponding  alcohols,  by  treatment  with  TFA  to  
give tri and tetracyclic products (165a–c) (Scheme 17) up to moderate yields (8–30%) and 
with the same stereochemistry as for compounds (164) (1H NMR). Compound (165b) was 
isolated as a single regio and stereoisomer. The carbonyl group of the indazolone moiety 
was located on the same side as the hydroxy group of the cyclohexanol ring and proven by 
X-ray crystallography (165b). 
5.2 Synthesis of a tricyclic model compound targeting PKC C1b 
By  using  the  X-ray  crystal  structure  of  the  PKC? C1b domain combined with molecular 
modeling, (3-aminodecahydro-1,4-methanonaphthalen-2-yl)methanol (166a) was 
discovered as a novel C1 domain ligand. Docking simulations suggested that (166a) would 
be well accommodated in the PKC? binding site (Figure 16). As illustrated in Figure 2, 
phorbol 13-O-acetate binds inside a groove on the PKC? surface, forming a network of five 
hydrogen bonds.149 This network involves two hydroxy and one carbonyl groups from 
phorbol 13-O-acetate that interact with the main chain amide and side chain hydroxy groups 
of Thr242, the main chain amide and carbonyl groups of Gly253, and the main chain 
carbonyl group of Leu251 from the protein. Similar interactions are suggested by the 
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docking simulations, whereby the hydroxy group of (166a) interacts with the main chain 
amide and side chain hydroxy groups of Thr242, and the amino group of (166a) accepts 
hydrogen bonds from both the carbonyl group of Leu251 and from that of Gly253. 
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Figure 16.  A) Structures of 1,2-diacylglycerol (DAG, 104), phorbols (105, 92) and ?-amino 
  alcohols (166a–b). B) (166a) docked in the crystal structure of the PKC? C1b 
  domain148 The C1b domain is represented as a transparent green surface and the 
  secondary structure colored cyan. The hit compound (166a) and the residues are 
  presented in ball and stick representation and colored by atom type. Hydrogen 
  bonds are shown as white spheres. The figure was created using ICM-Browser 
  (version3.7-2a, MolSoft L.L.C.). 
 
The synthetic endeavor of constructing the decahydronaphthalene core started from a 
known endo-norbornen-5,6-cis-dicarboxylic anhydride (167)33 that is preprarable in high 
yield from cyclopentadiene (49) and maleic anhydride (Scheme 18). The compound (167) 
was used as a dienophile for the next/subsequent [4+2]-cycloaddition reaction with 1,3-
butadiene, generated in situ from its 3-sulfolene precursor in the presence of 0.07 equiv of 
phenothiazine as a chemical stabilizer. Under the forcing reaction conditions (160–170 °C, 
sealed tube, 2 d) the non-activated double bond of (167) undergoes the D-A cycloaddition 
with 1,3-butadiene to give the bridged tricyclic meso-anhydride (168)260 (Scheme 18).  
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Scheme 18. The tandem Diels-Alder sequence to construct the six continuous stereocenters of 
meso-anhydride (168)260 via endo-(167). 
 
Up to 20% yield was produced (the crude product exo/endo-ratio ~ 4:1 by GC–MS) in 
multigram scale, and importantly as a single diastereomer after a single recrystallization 
from acetone. Meso-anhydride (170) presented the desired exo-stereochemistry in the fused 
cyclohexene ring as reported previously by Alder et al.260 
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The anhydride (168) was subjected to a one-pot catalytic hydrogenation and 
methanolysis step (H2,  Pd/C,  EtOAc/MeOH,  ?,  3  d)  to  give  the  ester  (169a) with a 
completely reduced decahydronaphthalene core, isolated as a single diastereomer in high 
yield (89%, Scheme 19). Methanolysis of alkene (168) produced (169b) nearly 
quantitatively (98%, Scheme 19). The key reaction in the introduction of the amino 
functionality in (169a–b) was the use of the modified Curtius-Schmidt rearrangement 
reaction. The carboxylic acid (169a) was first converted into the corresponding isocyanate 
via an acyl azide intermediate using diphenylphosphoryl azide (DPPA).261 A one-pot 
reaction in the presence of triethylamine and benzyl alcohol gave carbamate (170a) in 
moderate yield (40–50%) after chromatographic purification (Scheme 19). However, when 
(169b), bearing a cyclohexene moiety was subjected to the same Curtius-Schmidt 
rearrangement conditions, the Cbz-amine (170b) was isolated in higher yield (68%), and 
more importantly, as a solid reaction product. This, in turn, enabled us to carry out its single 
crystal X-ray structure analysis, which unambiguously confirmed the chemical structure of 
(170b) in the solid state (Scheme 19). 
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Scheme 19. One-pot Curtius-Schmidt rearrangement of hemiesters (169a–b) to the Cbz-
  protected amines (170a–b). ORTEP diagram of the molecular structure of (170b). 
 
The removal of the Cbz-protection group of compound (170a) by catalytic hydrogenation 
(H2, Pd/C, EtOAc, 2–3 h) gave the corresponding amine (171) (57%, Scheme 20). 
Subsequent reduction with LiAlH4, however, was not successful, since the incomplete 
reaction was followed by purification difficulties. Therefore, the order of synthetic sequence 
was  reversed.  The  reduction  of  the  methyl  ester  in  (170a) with LiAlH4 was conducted at 
low temperature (-50 to -20 °C) since the nucleophilic intramolecular side reaction 
(formation of the cyclic carbamate by elimination of benzyl alcohol) was found to take 
place at ambient temperature. At this time the primary alcohol (172) was obtained in 59% 
yield after column chromatography on SiO2 (Scheme 20). The final catalytic hydrogenation 
step reduced the fused cyclohexene ring and removed the carboxybenzyl group (H2, Pd/C, 
EtOAc,  rt,  3  h,  Scheme  20)  giving  (±)-cis-(3-aminodecahydro-1,4-methanonaphthalen-2- 
yl)methanol (166a) as a pure compound. 
To convert the amino functionality of (166a) to a more hydrophobic one, its N–methyl 
derivative (166b) was synthesized, since the C1 domain is thought to be partly buried in the 
membrane bilayer during PKC activation.149,151 The direct N–monomethylation of primary 
amines is known to be a difficult task in preparative synthetic chemistry, and harsh reaction 
conditions, poor yields, and low selectivity are the major limitations of direct N-methylation 
reactions  of  primary  amines.  However,  the  use  of  the  Cbz-protection  group  in  (170b) 
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allowed its N-monomethylation under mild conditions. Deprotonation of (170b) with NaH 
in DMF, followed by treatment with iodomethane, gave the N–methyl derivative (173) 
(77%) without affecting the cis, endo relationship of the carboxymethyl and Cbz-amino 
groups (Scheme 20). The Cbz-protected ?-aminomethyl alcohol was obtained conveniently 
from the parent alkene (173) under the same reaction conditions used for the preparation of 
the compound (172), and it was subjected to the catalytic hydrogenation without further 
purification. (±)-[cis-3-(Methylamino)decahydro-1,4-methanonaphthalen-2-yl]methanol 
(166b) was isolated and converted to the hydrochloride salt (2 M HCl in Et2O) in 90% yield 
(over 2 steps). 
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Scheme 20.  Synthesis of ?- amino alcohols (166a and 166b) by the successive reduction and 
  catalytic hydrogenation sequence. 
 
The synthesized (3-aminodecahydro-1,4-methanonaphthalen-2-yl)methanols (166a–b) were 
assayed for binding to the C1 domain of recombinant human PKC?? ?and  PKC? using a 
filtration method in a 96-well plate format. Crude cell lysates of Baculovirus-infected Sf 9 
cells were used as the source for PKC in the assay; lysate from uninfected Sf 9 cells did not 
exhibit phorbol ester binding (data not shown). The compounds were tested at a 
concentration range of 0.3–20 ?M. The results revealed that (166a and 166b) were unable 
to displace [20-3H]phorbol-12,13-dibutyrate from PKC? and PKC? (data not shown). 
Further work is being conducted in an effort to modify the synthesized compounds. 
5.3 Synthesis of new guaiazulene derivatives  
5.3.1 Synthesis of 4-aminoguaiazulene and its ?-lactam derivatives 
During the course of these studies, the introduction of a heteroatom into this structure was 
considered in order to modify the guaiazulene structure. This modification would be 
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especially interesting as nitrogen-substituted azulene derivatives are scarcely documented in 
the literature. Therefore, a method for nitrogen insertion into the 4-position of the 
guaiazulene (2) seven-membered ring was developed. This approach offered the possibility 
of synthesizing a number of new heterocyclic azulene derivatives. Modification of the 4-
position of guaiazulene (2) is feasible due to the enhanced acidity of the C–H bond in its 
methyl group, a procedure that reflects a common strategy in the field of azulene chemistry. 
Aumüller has previously utilized this strategy for the three-step synthesis of 7-isopropyl-1-
methylazulene-4-carboxylic acid (174)262 starting  from  (2) (Scheme 21). Treatment of 
guaiazulene (2) with LDA, followed by addition of isoamyl nitrite, yields N-oxime (175) in 
modest yield (28%); however, the subsequent dehydration with N,N-carbonyldiimidazole 
yields nitrile (176) in nearly quantitative conversion. The nitrile (176) tolerates harsh 
reaction conditions and can therefore be subjected to strong basic conditions (KOH, 10 
equiv) under prolonged heating in refluxing EtOH/H2O-mixture (90 °C, 10 days), where the 
two-step hydrolysis via a primary amide intermediate finally gives the carboxylic acid (174) 
(Scheme 21). 
 
 
Scheme 21.  Preparation of 7-isopropyl-1-methylazulene-4-carboxylic acid (174).264  
 
This crystalline and stable aryl carboxylic acid (174) was used as a starting material for the 
synthesis of nitrogen-substituted azulene derivatives. The key reaction in the preparation of 
amine (177) was the use of the modified Curtius-Schmidt rearrangement. The carboxylic 
acid (174) was first converted into the corresponding isocyanate via an acyl azide 
intermediate using diphenylphosphoryl azide (DPPA).261 A one-pot reaction in the presence 
of triethylamine and an alcohol gave carbamates (178a–c) in variable yields (Scheme 22). 
For example, when methanol and tert-butyl alcohol were used, the yields were only 
moderate (12–33%). However, in the case of benzyl alcohol the reaction proceeded well, 
and benzyl (7-isopropyl-1-methylazulen-4-yl)carbamate (178c) was isolated in high yield 
(82%) after silica gel column chromatography. Subsequent deprotection of the Cbz-
protected amine of (178c) turned out to be challenging, as standard methods, such as 
catalytic hydrogenation or acidic hydrolysis with HBr, suffered from the participation of the 
azulene moiety in numerous side reactions. Removal of the benzyl carbamate protective 
group was achieved in the presence of potassium hydroxide in an aqueous solution of THF 
and MeOH. When compound (178c) was heated with KOH in THF–MeOH–H2O, the color 
of the reaction mixture changed quickly from blue to deep purple. The hydrolysis was 
complete in 1–1.5 h (TLC monitoring) and 7-isopropyl-1-methylazulen-4-amine (177) 
(Scheme 22) was isolated in good yield (76%) after column chromatography on silica gel. 
Amine (177) was found to be relatively stable when stored under an inert atmosphere in a 
refrigerated toluene solution (~0.10 mM). 
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Scheme 22.  Synthesis of 4-aminoguaiazulene (177) from the known carboxylic acid (174). 
 
In agreement with previous work in our laboratory32, 7-isopropyl-1-methylazulen-4-amine 
(177) reacted with various 1,2-dicarbonyl compounds (40a–b) (Scheme 23). The cascade 
reactions yielded ?-lactams under mild reaction conditions without the need for a catalyst 
and produced a new six-membered ring fused to the azulene aromatic system. The one-pot 
reaction between (177) and methyl 3,3,3-trifluoropyruvate (40a) proceeded efficiently and 
yielded ?-lactam (179a) in 88% yield after purification by column chromatography. 
Theoretically, this reaction could have led to two regioisomeric products, but only one 
product was isolated. The azulenyl amine reacts in a similar fashion to that reported for the 
pure hydrocarbon guaiazulene.32 
 
The high nucleophilicity of the guaiazulenes electron-rich 3-position ensures that 
electrophilic substitution of this carbon atom is the predominant reaction between (177) and 
(40a) to yield (180) (Scheme 23), this is followed by a ring closure to furnish (181). Finally, 
the elimination of methanol produces ?-lactam (179a). The regioselectivity is further 
explained  by  the  high  electrophilicity  of  the  central  carbon  atom  of  the  doubly  activated  
dicarbonyl reagent. The reaction with diethyl ketomalonate (40b)  is  comparable to that of 
(40a)  (Scheme  23).  Reaction  of  amine  (177) at room temperature for 21 h yielded the 
corresponding lactam (179b) in 85% isolated yield after purification by column 
chromatography. In contrast, these types of cyclizations do not run smoothly with carbonyl 
reagents being not additionally activated, such as ethyl pyruvate, 2,3-butanedione, and ethyl 
glyoxylate. In these cases, lactam product was not obtained. However, other very reactive 
dicarbonyl reagents can be successfully employed, demonstrating that a broader structural 
variety is accessible by analogous reaction procedures.  
For example, we found that a rapid reaction occurs between amine (177) and oxalyl 
chloride (182) (Scheme 23). When the reaction temperature was as low as ?60 °C and an 
excess of the tertiary base (Et3N) was used, compound (183) was obtained in moderate 
(30%) yield after purification by column chromatography. In contrast to the ?-
hydroxylactams (179a–b) the product (183) contains a different functional group and is an 
?-ketolactam. 
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Scheme 23.  Cyclisation of 4-aminoguaiazulene (177) to six-membered lactams (179a–b, 183) 
and proposed reaction mechanism for the formation of (179a). 
5.3.2 Synthesis of tricyclic benzo[cd]azulenes as potential Pim-1 inhibitors 
Analysis  of  the  biological  effects  of  new  tricyclic  benzo[cd]azulenes led to their 
identification as potent and selective inhibitors against Pim family kinases. These 
compounds inhibit the phosphorylation of Pim substrates and reverse the anti-apoptotic 
effects  of  Pim  kinases.  They  also  prevent  migration  of  PC-3  prostate  cancer  cells  and  
significantly suppress the proliferation of lymphoblastoid cell lines infected and 
immortalized by the Epstein-Barr virus. Therefore, the discovered benzo[cd]azulene 
compouds could be promising Pim-selective inhibitors for both research and therapeutic 
purposes. 
Recently, Aumüller et al. developed a facile one-pot method for transformation of 
guaiazulene derivatives into new tricyclic heptafulvenes (44) (Figure 17).32 These 
compounds have a functionalized and fused six-membered ring on a benzo[cd]azulene 
skeleton. Furthermore, these heptafulvenes (44) were prone to oxidative cleavage when 
treated with a mild oxidant mCPBA  (meta-chloroperoxybenzoic acid), yielding the 
corresponding tricyclic tropones (48) (Figure 17). In addition, the same authors reported a 
tautomerization reaction that proceeds via isomerization  of  ?-bonds  across  the  azulene  
moieties of tricyclic benzo[cd]azulen-3-ones (36) derived from the parent 4,5-
dihydrobenzo[cd]azulen-3-ones (35).31 This efficient synthetic route produced 
heptafulvenes (39) (Figure 17) with a regioisomeric substitution pattern on the aromatic six-
membered ring.31 
 
Benzo[cd]azulenes are selective inhibitors against Pim family kinases  
 
Six of the previously reported compounds (Figure 17) were used at 10 ?M concentrations 
against a panel of 71 different protein kinases and screened for residual kinase activities less 
than 50%.263 The results are presented in Table 1 of manuscript IV (appendix). Two of the 
tested compounds (44a and 36c) significantly reduced the in vitro activities of Pim family 
members, especially Pim-1 and Pim-3 (Table 1 of manuscript IV). Compound (44a) 
showed clearly more selectivity than (36c), but also had some inhibitory activity against 
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PRAK (p38-regulated/activated protein kinase), p38g (mitogen-activated protein kinase) 
and some DYRK (dual specificity tyrosine-phosphorylation-regulated kinase) family 
members. Compounds (48a)  and  (184)  were  also  active  against  Pim-1  and  Pim-3  and  
demonstrated more selectivity than (44a). Interestingly, the structurally similar compounds 
(44e) and (36b) showed hardly any activity in in vitro kinase assays. It should be mentioned 
that  the  resulted  screening  gives  only  rough  estimatation  on  the  kinase  specificity  of  the  
compounds. 
 
 
Figure 17.  Some of the benzo[cd]azulenes and benzo[cd]azulen-3-ones by Aumüller  et al.31,32 
 
Synthesis of new benzo[cd]azulene derivatives: Modification of the carbonyl functionality  
 
The promising results on Pim kinase inhibition in multiple cell-based assays led to a further 
modification of the azulenes, heptafulvenes, and tropones presented in Figure 17. The aim 
was to develop derivatives that would be even more potent as Pim kinase inhibitors than 
previously reported benzo[cd]azulenes. Tropone (48a)32 was used as a key intermediate, 
since it was easily prepared in high yield (82%) from the parent heptafulvene (44a) and 
accessible to chemical modification through its carbonyl group. In addition, it was shown to 
be a potential and Pim selective kinase inhibitor. The exocyclic C=C double bond was 
restored in a single transformation, when (48a) was subjected to the Knoevenagel 
condensation with malononitrile. The reaction was catalyzed by ammonium acetate and 
gave highly conjugated dicyanoheptafulvene (185a) in 45% yield (MeOH, reflux, 2–3 d, 
Scheme 24). An analogous two-step synthesis of similar dinitrile system is reported via 
ethoxytropylium fluoroborate.264 The electron withdrawing cyano groups are known to have 
a stabilizing effect on heptafulvenes. The crystalline product (185a) can be stored at room 
temperature over a prolonged period and shows good chemical stability in aqueous 
solutions. Demethylation of the aryl methyl ethers on tropones (48a, 184) was found to be 
unsuccessful under standard conditions (BBr3, 2–4 equiv, CH2Cl2, rt, 2–8 h). Therefore the 
free phenol analog (48c)32 (Figure 17) was synthesized and subjected to the Knoevenagel 
condensation  (malononitrile,  MeOH,  reflux,  4  d)  to  give  the  phenolic  dinitrile  (185b) 
(Scheme 24). The carbonyl group of (48a) was transformed into the oxime functionality by 
treating it with hydroxylamine hydrochloride in the presence of ammonium acetate in a 
mixture of isopropanol–water (3:1) for a prolonged time (5 d, 80 °C, Scheme 24). Two 
stereoisomers were separated by a careful column chromatography on silica gel followed by 
recrystallization (EtOAc/n–Hex) to give pure Z and E isomers (NMR, NOE assignment) of 
oximes (186a)  (42%,  yellow  needles)  and  (186b) (29%, orange needles). Under these 
reaction conditions, no 2-aminotropone derivatives (187) (Scheme 24) were formed, as has 
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been previously reported for the tropone itself to produce a mixture of products.265 The 
analogous reaction for (48a) in the presence of hydrazine monohydrate (MeOH, reflux, 20 
h) (Scheme 24) yields hydrazide product (188) as an inseparable E/Z-mixture. Again none 
of the 2-amino-substituted products were isolated, which is in contrast to the previous 
observations in the related tropone systems.265 
 
 
Scheme 24. Modification of tropone carbonyl function in synthesis of new derivatives. 
 
Derivatization of the double bond of the five-membered ring  
 
Catalytic hydrogenation of (48a) gave one main product after chromatographic isolation. 
Instead of reduction of the C=C double bonds in the seven-membered ring as reported for  
the smilar 3,4-fused benztropone (189),265 it was found that the double bond in the five-
membered ring of (48a) was more susceptible to catalytic hydrogenation, when the reaction 
conditions were carefully controlled (Scheme 25, H2, 10% Pd/C, EtOAc, 0 °C, 50 min). The 
racemic non-planar compound (190) was obtained in 40% yield.  
The double bond in a five-membered ring showed regioselectivity towards oxidation 
when tropone (48a) was treated with an excess of mCPBA for a prolonged reaction time (3 
equiv, rt, 5 d) giving the racemic epoxide (191) (Scheme 25) as a main product in 42% yield 
after column chromatography. The epoxide in (191)  was  prone  to  the  acid-catalyzed  ring  
opening (perchloric acid) to give trans-diol (192a) (Scheme 25) in high yield (89% after 
column chromatography). The corresponding cis-diol (192b) was synthesized directly from 
the  alkene  (48a)  by  using  a  catalytic  amount  of  osmium  tetroxide  (OsO4) and N-
methylmorpholine N-oxide (NMO) as a co-oxidant. The diols (192a–b) showed improved 
solubility in protic solvents and were colorless compared to the previously synthesized 
strongly colored tropones (yellow/orange). 
In the presence of phosphonium ylides the ???–unsaturated ketone moiety of tropone 
(48a) was found to undergo 1,4-conjugate addition reaction instead of the expected Wittig 
reaction (Scheme 25). The low temperature (–78 ?C) addition of ylide 
(methoxymethylene)triphenylphosphorane to (48a) gave one main product (193) in 38% 
yield after aqueous acidic work-up and chromatographic purification. Extensive 2D NMR 
(HMBC, HSQC, and NOESY) analysis unveiled that (193) had an unexpected structure of a 
non-planar quaternary aldehyde at carbon C9a (Scheme 25). 
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Scheme 25. Reduction and oxidation reactions of the five-membered ring in benzo[cd]azulenes 
  and an example of the regioselective 1,4-conjugate addition. 
 
Functionalization of the phenolic 4-position 
 
The phenolic 4-position of benzo[cd]azulene (48c) is easily accessible for the attachment of 
various functional groups under mild reaction conditions. For example, propargylation of 
the phenol (48c) (K2CO3,  propargyl  bromide,  acetone,  rt,  48  h)  gave  terminal  alkyne  
(144)266 (Scheme 26) in 62% yield, which was used in microwave-assisted, copper–
catalyzed azide alkyne cycloaddition267 (Scheme 26, one-pot: BnBr, NaN3, CuSO4, Na-
ascorbate, DMF–H2O, 4:1, MW, 35 min) to give a tropone analog (145)266 as a single 1,4-
regioisomeric product with the 1,2,3-triazole side chain.  
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Scheme 26. Functionalization of the phenolic 4-position. 
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Several known Pim-1 inhibitors take advantage of the interaction with the positively 
charged amino residue of Lys67 on the binding pocket of Pim-1. Therefore, negatively 
charged carboxylate residue was attached to the benzo[cd]azulene framework to possibly 
make an ionic interaction with Lys67. This was achieved by deprotonation of phenol (48c) 
with potassium carbonate followed by treatment with methyl bromoacetate to give acetate 
(146)266 as a crystalline solid (Scheme 26). Hydrolysis of (146) with LiOH in THF–MeOH– 
H2O–acetone gave the tricyclic acetic acid derivative (147)266 in 96% yield. 
 
Functionalization of the 3-position of benzo[cd]azulen-3-ones 
 
In this study, benzo[cd]azulen-3-one (36c) was synthesized from guaiazulene (2) with a 4-
step procedure.31 The acid-catalyzed tautomerization reaction of (36c) presented in Chapter 
2 produces heptafulvene (39c) as a trifluoromethyl ether in high yields after in  situ  O-
methylation of the 3-position. In a similar manner, the enolization of (36c), followed by a 
treatment with methyl bromoacetate, yields a new heptafulvene (194)268 with a glycolate 
side chain on the 3-position (63% yield) (Scheme 27). Both heptafulvenes (39c, 194) were 
further modified by oxidizing them with mCPBA.  Novel  tropone  methyl  ether  (184) was 
isolated in high yield (85%) as a regioisomer of the heptafulvene 48c (Scheme 27). 
Oxidation of (194) gave acetate (195), which was hydrolyzed under the same conditions as 
(146)  (vide infra) to give a novel tropone derivative (196)268 with  the  acetic  acid  residue  
now on the 3-position and as a regiosiomer of (147).  
  The  isolation  of  the  phenol  (38) of benzo[cd]azulen-3-one (36c) (Scheme 27) is not 
possible since the reverse nature of a tautomerization reaction and therefore phenolic 
products cannot be synthesized. The demethylation of the aryl methyl ethers on tropones 
(48a, 184) to phenolic products with standard reagent (BBr3) is also inefficient. However, to 
overcome this problem, a cleavable phenolic tautomer could be trapped as a silyl enol ether. 
This strategy was demonstrated in the efficient two-step synthesis, where the phenol 
tautomer (38) is generated first in situ (HCl, cat., THF, rt, 20 min) and, after deprotonation, 
derivatized by silylation (NaH, 5 equiv and TBDMSCl 2.5 equiv, rt, 2–3 h) to give (197) in 
high 84% yield (Scheme 27). This allowed the mCPBA oxidation of the exo-double bond of 
heptafulvene (197), followed by a removal of the TBDMS-protection group by a 1.0 M 
solution of TBAF (tetrabutylammonium fluoride) in THF (1.2 equiv, THF, rt, 2 h) to finally 
give  the  troponoyl  phenol  (198) (Scheme 27) as a regioisomer of the benzo[cd]azulene 
(48c). 
 
Scheme 27. Use of the acid-catalyzed tautomerization reaction in synthesis of regioisomeric 
  benzo[cd]azulenes.  
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Nucleophilic conjugate addition reactions of benzo[cd]azulen-3-one 
 
The utilization of benzo[cd]azulen-3-one (36c) was not only restricted in synthesis of new 
regioisomeric heptafulvenes and tropones. Benzo[cd]azulen-3-one (36c) was discovered to 
undergo efficient and regioselective 1,4 and 1,6-conjugate addition reactions with various 
soft and hard nucleophiles (Scheme 28).266 In an interesting example, the sulfur nucleophile 
(benzylthiol) reacts preferentially to the five-membered ring of benzo[cd]azulen-3-one 
(36c). Thus a regioselective 1,4-attack yields benzylthiol-substituted phenolic 
benzo[cd]azulene (148) (Scheme 28). Despite the fact that product (148)  is  prone  to  
decomposition when exposed to an acidic environment (SiO2) in the purification by column 
chromatography, it is isolable in high 81% yield.266  
 
 
Scheme 28. 1,4-Conjugate-addition reactions of benzo[cd]azulen-3-one to phenolic products. 
 
Interestingly, the carbonyl group of benzo[cd]azulen-3-one (36c) did not undergo a typical 
Wittig reaction, but rather a conjugate addition reaction in the presence of methoxycarbonyl 
and nitrile-group stabilized phosphonium ylides. These preliminary studies of a reaction 
between (36c) and (triphenylphosphoranylidene)acetonitrile yielded a complex mixture of 
products (TLC). However, when benzo[cd]azulen-3-one (36c)  was  allowed  to  react  with  
methyl (triphenylphosphoranylidene)acetate in anhydrous THF (?15 °C to rt, 1.5 h), the 
green starting material disappeared completely with formation of a single reaction product 
(149) (Scheme 28).266 The phosphine compound (149)  was  isolated  as  a  yellow  solid  in  
70% yield, although some of the material was lost during the purification by column 
chromatography since (149) is unstable in acidic media. 
    These two examples of conjugate addition reactions were performed at ambient 
temperature or even below 0 °C and they proceeded well even without any added catalyst to 
produce new types of tricyclic non-planar structures with a phenolic functionality on a 
benzo[cd]azulene skeleton  
 
The reactivity of benzo[cd]azulen-3-one (36c) towards oxygen nucleophiles was also 
studied, but a reaction between phenol and (36c) failed to give any products. 
Benzo[cd]azulen-3-one (36c)  even showed resistance to react in the presence of an excess 
of more nucleophilic oxygen species, such as phenolate anion (phenol, K2CO3,  EtOH,  rt)  
under prolonged reaction time (24 h) resulting only in partially decomposed starting 
material.266  
During the attempts to manipulate benzo[cd]azulen-3-one (36c), the chemical behavior 
of its carbonyl group was found to have some odd qualities. A condensation reaction 
between ketone (36c) and hydroxylamine was assumed to give N-oxime reaction products 
(199) via the conventional 1,2-addition reaction (Scheme 29). However, when (36c) was 
heated in the presence of hydroxylamine hydrochloride (8 equiv) and ammonium acetate in 
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refluxing methanol for 3 days (Scheme 29), the isolated reaction product was not an oxime, 
despite the identical molecular weights of two products (LC–MS: [M+H]+ m/z 320).  It  is  
assumed that hydroxylamine undergoes 1,4-conjugate addition to the 2-position of 
benzo[cd]azulen-3-one (36c) to give the initial phenolic intermediate (200) (Scheme 29). 
Protonation of the hydroxy moiety on the NHOH-group in slightly acidic reaction media is 
followed by an intramolecular attack of the phenolic hydroxy of (201) to the nitrogen atom. 
This leads to the scission of the labile N-O single bond as water is eliminated out and to the 
formation of the transient five-member heterocyclic (isoxazole) ring in (202) (Scheme 29). 
In the final step, a 1,5-hydrogen shift of a methine proton in (202) restores the carbonyl 
group of benzo[cd]azulen-3-one and releases the amino group to the 2-position by opening 
the intermediate five-member ring. 2-Aminobenzo[cd]azulen-3-one (150)266 is isolated as a 
main reaction product in 38% yield after column chromatography (Scheme 29). 
 
According to the 1H NMR studies, the NH2 group of (150) gives two separate signals and 
can therefore be distinguished (DMSO-d6: ? 9.03 and 8.77 ppm). The two separate signals 
are rationalized to be a result of a lack of free rotation around C–NH2 bond, caused by a 
likely intramolecular hydrogen-bond (dashed line) between N-H and C=O in the 
benzo[cd]azulen-3-one (150) (Scheme 29). The presence of a carbonyl carbon at the 3-
position of product (150), rather than a tautomeric phenol structure, was proven by the 13C 
NMR spectra, where the chemical shifts of the C=O of product (150) and starting material 
(36c)  were  identical  (? 174.9 ppm).266 The constitution of compound (150) was further 
confirmed by its high-resolution mass spectra (HRMS-ESI m/z:  calc.  for  C18H16F3NO 
[M+H]+: 320.1262, found 320.1262). 
 
Scheme 29. A tentative reaction mechanism for the formation of 2-aminobenzo[cd]azulen-3one. 
 
Further in vitro and cell-based characterization of benzo[cd]azulenes 
 
To define the efficacy of the synthesized compounds, in vitro kinase assays were performed 
with bacterially produced human Pim-1 protein, to measure its residual activity. To confirm 
the  preliminary  results  shown  in  Table  1  of  manuscript  IV (appendix), the previously 
synthesized compounds were used as controls. All the previously tested compounds resulted  
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in very similar residual Pim-1 activities to those presented in Table 1 (manuscript IV). To 
qualify whether benzo[cd]azulenes can enter the cell and inhibit intracellular Pim kinase 
activity, the the cell-based assays were carried out. In these assays, FDCP1-derived cell 
lines that had been stably transfected with either neomycin (FD/Neo) or the 44 kD isoform 
of Pim-1 (FD/Pim44) were used. In these assays a potent Pim inhibitor would reduce the 
survival of FD/Pim44 cells to the level of FD/Neo control cells, but would not have severe 
cytotoxic effects. The metabolic activity of the cells was measured to quantify the effects of 
the benzo[cd]azulenes on cell viability.  
  In these assays benzo[cd]azulenes (44a) and  (184) reduced the metabolic activity of 
FD/Pim44 cells  to  the  level  of  FD/Neo cells.  By contrast,  structurally  similar  compounds  
(36b)  and  (44e) remained ineffective in these assays. While (36c) initially displayed no 
efficacy, additional experiments with newly prepared and freshly dissolved sample 
demonstrated its high potency, but also cytotoxicity, which is why heptafulvene (44a) and 
tropone (184) were used in further biological assays (data not shown). 
  The calculation EC50 (effective concentrations) values for (44a) and (184) showed nearly 
similar concentrations in both FD/Neo (5.2 and 6.9 µM) and FD/Pim44 (3.2 and 6.1 µM) 
cell lines, respectively.  
The results of in vitro activities and cell viabilities are presented in Table 2 of manuscript 
IV. Compounds not included in the manuscript IV are listed in Table 2 (vide infra). 
 
Table 2.  Residual Pim-1 kinase activity (%) and cell viability (%) in the presence of 
benzo[cd]azulenes (10 ?M and 0.5–5.0 ?M, respectively). 
Structure 
 
Compound,  
ref. 
Residual 
Pim-1 
activity 
Residual viability 
of  FD/Neo 
cells 
Residual 
viability of 
FD/Pim44 cells 
 
(194)268 59 – – 
 
(195)268 87 – – 
 
(196)268 67 – – 
 
(144)266 119 – – 
 
(145)266 58 – – 
 
 
67 
 
 
(146)266 113 – – 
 
(147)266 67 – – 
 
(148)266 28 32 (0.5 ?M) 58 (0.5 ?M) 
 
(149)266 26 38 (1.5 ?M) 35 (1.5 ?M) 
 
        (150)266 37 62 (5.0 ?M) 48 (5.0 ?M) 
 
Structure–activity relationships of benzo[cd]azulenes and conclusions 
 
The results from in vitro activities and cell-based assays were used for structure-activity 
relationship studies (Table 2, manuscript IV).  In the heptafulvenic series compound (44a) 
with the trifluoromethyl and methoxy substituents on 3- and 4-positions displayed a 
promising residual Pim-1 kinase activity of 43%. In addition, (44a) was even more effective 
against Pim-3 (residual activity of 30%). The regioisomeric heptafulvene (39c) was nearly 
as active against Pim-1 (residual activity 46%). In cell-based assays, compound (44a) 
reduced the metabolic activity of FD/Pim44 cells (cell viability 65%) without affecting of 
the FD/Neo control cells. By contrast, the regioisomeric heptafulvene (39c) was completely 
ineffective in these assays and rather showed some signs of off-target cytotoxicity (FD/Neo 
74%, FD/Pim44 97%). The free 4-phenol analog (44c) was discovered to be the most potent 
compound of heptafulvene series, with low residual Pim-1 activity (29%). Its chemical 
instability however excluded it out from the cellular assays. Replacement of hydroxy 
functionality in (44c) with a phenyl ring in (44e) increased residual Pim-1 activity to 59%. 
Regardless of moderate in vitro activity, compound (44e) displayed any potency on cellular 
assays. The heptafulvene (194) with an oxyacetate side showed moderate inhibition 
(residual activity 59%). The necessity of the trifluoromethyl substituent on the phenyl ring 
in effective inhibition of Pim-1 kinase was demonstrated by replacing it with a methyl 
group in (39b) with a complete loss of inhibitory activity. 
   The tropones (48a) and (184) oxidized from the parent heptafulvenes (44a) and (39c)  
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were both slightly less potent with (residual activities of 74% and 58%, respectively). Later 
during the cellular assays it was recognized that tropone (48a) showed signs of non-specific 
cytotoxicity by affecting both the FD/Neo and FD/Pim44 cells (80%, 81%, respectively). 
However, its regioisomer (184) efficiently impaired the pro-survival advantage of Pim-1 
overexpression in FD/Pim44 cells (69%) without any effects on FD/Neo cells.  Due to the 
presence of modificable carbonyl functionality and better chemical stability compared to the 
corresponding heptafulvenes, tropones were selected for further modifications.  
Alkylation of the 3- and 4-positions gave tropones (144) and (146) but with no inhibitory 
activity at all. The triazole-functionalized tropone (145) showed more effective inhibition 
(residual Pim-1 activity of 58%), however, being only partly soluble to DMSO solvent. The 
regioisomeric carboxylic acids (147 and 196) showed only moderate residual Pim-1 
activities (both 67%). When the trifluoromethyl substituent of (48a) was switched to an 
ethoxycarbonyl group in (48d), the kinase inhibitory activity was again completely lost 
(residual Pim-1 activity 98%). Tropone (48c) with a phenolic residue at 4-position was the 
most potent compound synthesized with residual Pim-1 activity of only 11%. Despite very 
promising in vitro kinase activity; in cell-based assays (48c) was disappointingly far less 
effective and showed signs of off-target cytotoxicity (FD/Neo 85%, FD/Pim44 83%). By 
contrast, its regioisomer (198) synthesized in this study was far less potent with residual 
Pim-1 activity of 65%. 
The five-membered ring of (48a) was subjected for further modifications where the 
epoxide (191) showed moderate activity (residual activity 65%). The cis- and trans–diols 
(192b)  and  (192a) demonstrated slightly better in vitro activities against Pim-1 (residual 
activities 55% and 69%, respectively). However, it should be mentioned that both of these 
compounds showed a great improvement of solubility into protic solvents. The non-planar 
alkane (190) regioselectively hydrogenated from (48a) was completely inactive. However, 
the quaternary aldehyde (193) with a non-planar structure, proved to be a potent inhibitor of 
Pim-1 (residual activity 34%). In the cell-based assays it unfortunately showed obvious 
signs of non-specific cytotoxicity (FD/Neo, FD/Pim44, both 64%). 
The troponoyl carbonyls on the 8-position of tropones (48a)  and  (48c) were further 
modificated. The malononitrile derived heptafulvenes (185a)  and  (185b) resulted in 
moderate to effective (residual activities 60% and 41%, respectively) residual Pim-1 
activities. Despite of dicyanoheptafulvene (185a) only moderate in vitro activity, it 
displayed similar properties as (44a)  and  (184) and efficiently impaired the pro-survival 
advantage of Pim-1 overexpression in FD/Pim44 cells (viability 61%) However, (185a) also 
affected the Neo expressing control cells (78%). By contrast, the more in vitro potent 
phenolic (185b) was completely inefficient in cell-based assays (FD/Pim44 93%).  
The  oximes  (186b)  and  (186a) were assayed separately as pure Z- and E-isomers, but 
were not found to be potent against Pim-1 (residual kinase activities 82% and 71%). 
Similarly, the hydrazide (188) (mixt. of Z/E isomers) showed only moderate inhibitory 
activity (64%).  
In the series of benzo[cd]azulen-3-ones, (35c) was only modestly active (residual Pim-1 
activity 74%) and (35b) ineffective (92%). The dehydrated 4-methyl analog (36b) was also 
ineffective (92%) but (36a) with no substituent at 4-position was moderately effective 
(62%). Compound (183) representing the group of heterocyclic azulene derivatives showed 
moderate residual activity (59%). The CF3-substituted compound (36c) showed moderate 
inhibition against Pim-1, but was surprisingly potent when tested against Pim-3 (residual 
activities 51% and 24%, respectively). However, on cell-based assays it dramatically 
reduced the cell viabilities of both cell lines (FD/ Neo 6%, FD/Pim44 3%). It is conceivable 
that the observed high activity of the benzo[cd]azulen-3-one 4c in cell-based assays results 
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from its enhanced reactivity with various nucleophiles.266 The more detailed study will be 
published in due course. Moreover, (36c) was found to be an potent inhibitor of Pim-3 
kinase with a residual activity of 24%.263 The azulene compounds derived from 
benzo[cd]azulen-3-one (36c) were tested against Pim-1. The 2-amino benzo[cd]azulen-3-
one (150) showed potent residual in vitro activity against Pim-1 (37%). The two phenolic 
compouds (148, 149) were even more efficient with residual activities of 28% and 26%, 
respectively.266 In  the  preliminary  cellular  assays  compounds  (148, 149 and 150) reduced 
efficiently the cell viabilities of both cell lines even at 0.5 ?M concentration. The detailed 
results covering synthesis and biological potency of these compounds will be published 
later in an individual article.  
 
The SAR analysis indicated that the presence of CF3-substituent on the phenyl ring plays an 
essential  role  in  the  effective  inhibition  of  Pim-1  kinase.  Moreover,  phenolic  structure  on  
benzo[cd]azulenes was important for effective Pim-1 inhibition; exemplified in (48c), 
(148), (149) and (185b) with the most efficient in vitro inhibitory activities.  
Intriguingly, the in vitro results of benzo[cd]azulenes did not always correlate with their 
efficacy in cell-based assays. While the tropone (48c) very potently inhibited Pim-1 activity 
in vitro, it was less efficient in cells and also showed some signs of cytotoxicity. By 
contrast, (184) displayed only mild effects in vitro, but was still almost as effective as (44a) 
in cell-based assays. The same fashion was seen within dicyano-derived heptafulvenes 
(185a)  and  (185b), where the less in vitro active (185a) was the second most effective 
compound in cell-based assays of the whole study.  
Ongoing development of additional benzo[cd]azulene derivatives is expected to further 
improve their efficacy as Pim-selective kinase inhibitors and putative anti-tumor drug 
candidates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
6 Summary and conclusions 
A practical solid-phase method for the preparation of biologically interesting heterocyclic 
six-membered compounds by the aza Diels-Alder reaction was developed. A variety of 
hexahydrocinnoline derivatives and related compounds were synthesized by this approach 
(I). The availability of carbonylazo dienophiles was restricted, during the study, since only 
one single compound (4-phenyl-1,2,4-triazole-3,5-dione) was commercially available. 
Therefore, a convenient two-step synthetic procedure was used in a parallel fashion to 
introduce the urazole compounds as bench-stable precursors of 1,2,4-triazole-3,5-diones in 
high yields. The semicyclic diene 3-vinyl-cyclohexen-1-ol was prepared for the study over 
two steps, followed by its efficient loading via benzyl ether to the commercially available 
bromo-Wang resin. The aza Diels-Alder reaction between polymer-bound diene and in situ 
generated N-aryl and N-alkyl 1,2,4-triazole-3,5-diones was performed at ambient 
temperature with no added catalyst. The subsequent acid-mediated cleavage of the benzylic 
C–O bond of the resin-bound cycloadducts took place in a traceless manner, with no sign of 
linker being detected. The typical isolated yields were modest, ranging from 8 to 53% over 
three reaction steps. Some of the cycloadditions were carried out in a parallel fashion. The 
cleaved cycloadducts were typically purified by column chromatography to ensure the high 
purity, although some of the reactions gave rather pure crude products. The stereochemistry 
of single diastereomeric cycloadducts was determined by 1H NMR spectroscopy and the 
results were consistent to those reported from solution-phase reactions. 
The hetero Diels-Alder method was successfully transformed to polymeric support. The 
advantages of a solid-phase method were in the isolation and purification of the resin, and 
the use excess reagents to help to drive the equilibrium towards the products. However, the 
major drawback of the developed method was the restricted access to multiple 
derivatization sites on both diene and dienophile components of the Diels-Alder reaction, 
which led to products with limited variation on the substituent sites.  
Some of the compounds were screened against a panel of 71 different protein kinases. 
The selected cycloadducts showed no significant kinase inhibition; however, these 
compounds could be used in the future as templates to diversify their chemical structures 
since these transformations are likely to provide access to even more functionalized 
heterocyclic compounds. 
 
Utilization  of  the  known X-ray  crystal  structure  of  the  PKC? C1b domain combined with 
molecular modeling led to a discovery of (3-aminodecahydro-1,4-methanonaphthalen-2-
yl)methanol (166a)  as  a  new  C1  domain  ligand  (III).  Various  synthetic  strategies  and  
methods  were  attempted,  including  two  Diels-Alder  routes  for  the  construction  of  the  
decahydronaphthalene core. Under the forcing reaction conditions, the bridged tricyclic 
meso-anhydride (168) was synthesized with its six continuous stereocenters, and in 20% 
yield, after some reaction optimization. The anhydride (168) was accessible in multigram 
scale and importantly as a single exo-diastereomer after recrystallization. The Curtius-
Schmidt rearrangement reaction was used for the installation of amino functionality to 
carboxylic acids derived from the anhydride (168). The single crystal X-ray structure 
analysis confirmed the chemical structure of the key intermediate (170b). The reduction of 
methyl ester, followed by a catalytic hydrogenation step, completed the synthesis of (±)-cis-
(3-aminodecahydro-1,4-methanonaphthalen-2-yl)methanol (166a). The Cbz-protecting 
group was utilized in the synthesis of the N–methyl derivative (166b). 
  Despite a successful preparation of the decahydronaphthalene core of ?-amino alcohols 
with the correct stereochemistry, the drawback of this synthetic route was the lack of 
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convenient generation of derivatives of (168)  by the selected Diels-Alder route.  The most 
disappointing fact was that the (3-aminodecahydro-1,4-methanonaphthalen-2-yl)methanols 
(166a, 166b) were unable to displace [20-3H]phorbol-12,13-dibutyrate from PKC? and 
PKC?, and therefore left the benefit of these compounds as PKC C1b ligands unclear. 
While both ?-amino alcohols were prepared and tested as racemates, synthesis of optically 
pure ligands may be achieved by desymmetrization of meso-anhydride (168) by asymmetric 
methanolysis. Further work is being conducted in an effort to modify the synthesized 
compounds. 
 
En route to new guaiazulene derivatives, we became interested in introducing a heteroatom 
into this structure. Therefore, a method for nitrogen insertion into the 4-position of the 
guaiazulene seven-membered ring was developed (II). This approach offered the possibility 
of synthesizing a number of new heterocyclic azulene derivatives. The aryl carboxylic acid 
(174) was converted to benzyl (7-isopropyl-1-methylazulen-4-yl)carbamate (176c) in high 
yield (82%) by the Curtius rearrangement reaction. The removal of the Cbz-protecting 
group under basic reaction conditions gave 7-isopropyl-1-methylazulen-4-amine (177) as a 
new aminoazulene derivative. Amine (177) can be purified by column chromatography on 
silica gel and is relatively stable when stored in a refrigerated solution under an inert 
atmosphere. The cascade reactions between (177) and various 1,2-dicarbonyl compounds 
yielded ?-lactams (179a–b) under mild reaction conditions without the need for a catalyst 
and produced a new heterocyclic six-membered ring fused to the azulene aromatic system. 
While only two ?-lactam products were synthesized in this study, the yields were high with 
a formation of single regioisomers. The cyclizations failed with carbonyl reagents that are 
not additionally activated (e.g. ethyl pyruvate, 2,3-butanedione, and ethyl glyoxylate). 
However,  other  very  reactive  dicarbonyl  reagents  such  as  oxalyl  chloride  can  be  used,  as  
demonstrated in the synthesis of ?-keto lactam (183). Further work is being conducted in an 
effort to expand the scope of the reaction and to investigate the biological properties of 
these compounds as potential inhibitors of Pim protein kinases. 
 
Recently, some of the benzo[cd]azulenes synthesized in our laboratory were characterized 
as selective Pim inhibitors when screened against a panel of 71 protein kinases. In addition, 
we found that treatment with benzo[cd]azulenes significantly slows down migration of 
adherent cancer cells derived from either prostate cancer or squamocellular carcinomas. 
Based on the promising results on Pim kinase inhibition in multiple cell-based assays, 
further  modification  of  the  azulenes,  heptafulvenes,  and  tropones  was  conducted  with  the  
aim of developing new derivatives of the original benzo[cd]azulene compounds (IV). 
Variation of multiple positions around the benzo[cd]azulene core was achieved, including 
manipulation of the troponoyl carbonyl function, derivatization of the double bond on the 
five-membered ring, and functionalization of the both 3 and 4 positions of the phenyl ring. 
Introduction of regioisomeric tropones and heptafulvenes of the most promising compounds 
was achieved. 
 
The most striking results of the whole study were obtained in the attempts to manipulate the 
carbonyl function of benzo[cd]azulen-3-one (36c). It was discovered that compound (36c) 
undergoes an efficient and regioselective 1,4-addition reactions with various soft and hard 
nucleophiles. In an interesting example, sulfur nucleophile (benzylthiol) leads to preferable 
1,4-attack to the five-membered ring of (36c) to produce (148). The single phenolic reaction 
product (148) is isolable as high as 81% yield, despite the fact that it is prone to 
decomposition during the purification by column chromatography on SiO2. 
72 
Interestingly, benzo[cd]azulen-3-one (36c) did not undergo a typical Wittig reaction but 
rather a conjugate addition reaction in the presence of a phosphonium ylide. Likewise in 
product (148), the nucleophilic addition took place at the five-membered ring and gave 
triphenylphosphonium ylide-substituted benzo[cd]azulene (149) as a sole reaction product. 
When heated in the presence of hydroxylamine, the ketone carbonyl of the compound (36c) 
did not follow the expected 1,2-addition reaction to give the N-oxime products. Instead, 
hydroxylamine undergoes a surprising 1,4-conjugate addition to the five-member ring of 
benzo[cd]azulen-3-one (36c). This leads to the scission of the N-O single bond as water is 
eliminated followed by the subsequent 1,6-hydrogen shift, which restores the carbonyl 
function and gives 2-aminobenzo[cd]azulen-3-one (150) as a main reaction product. 
These three examples of conjugate addition reactions were performed at ambient 
temperature or even below 0 °C (except (150)) and they worked well, even without any 
added catalyst, to produce a new type of tricyclic phenolic benzo[cd]azulenes. These results 
with detailed biological properties will be published in the future. 
 
Structure-activity studies of benzo[cd]azulenes revealed that thetrifluoromethyl substituent 
on the phenyl ring plays an essential role in the effective inhibition of Pim-1 kinase. This 
was demostrated with compounds bearing alternative arene substituent patterns, such as 
found in the methyl and ethoxycarbonyl analogs (39b)  and  (44d), both being completely 
inactive compounds. This study also showed that the presence of phenolic hydroxy on the 
six-membered ring of benzo[cd]azulenes was important for its effective activity. Tropone 
(48c), azulenes (44c),  (148)  and (149)  and heptafulvene (185b),  all  carrying a phenol as a 
common structural feature, showed the most effecient inhibitory in vitro inhibitory activity 
against Pim-1. By contrast, the regioisomeric tropone (198) showed only modest efficiency 
as compared to the above mentioned compounds. 
  The benzo[cd]azulenes detailed in this study were found to be useful research 
compounds as potential Pim-selective kinase inhibitors. Attempts to crystallize Pim-1 with 
benzo[cd]azulene compound for the X-ray structure determination are under way. 
Information from the possible X-ray crystal structure, combined with new synthetic 
methods developed in this study, will be valuable tools in further development of promising 
scaffolds of small molecule therapies against Pim-overexpressing invasive tumors and other 
tumorigenic disorders in the future. 
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